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Abstract
Breast cancer is a malignancy of the epithelial cells comprising the mammary
gland. As the ER is necessary for the growth of approximately 70% of breast cancers,
pharmaceutical efforts have focused on uncovering modulators of the ERα such as antiestrogens and Selective Oestrogen Receptor Modulator (SERMs). SERMs differ from
pure ER antagonists in their capacity to display tissue-selective and C promoter
dependent agonist-antagonist activities. Tamoxifen (TAM) is a SERM that is used in the
treatment of hormonally responsive breast cancer. TAM is the most commonly used
treatment for patients with ERα positive breast cancer.
In this study we examined the role of Oestrogen Receptor (ER) signaling in the
regulation of tissue Transglutaminase 2 gene (TGM2). TGM2 encodes tissue
Transglutaminase (TG2), a multifunctional enzyme with many cellular functions, such
as matrix remodelling, stabilization of apoptotic cells and cell adhesion and migration
which are thought to be implicated in inhibition of tumour growth and prevention of
metastasis. Ligand activated ER has been shown to induce the transcription of the
TGM2.
Our results show mRNA expression of TGM2 by E2/ER in breast cancer cells is
maintained in the presence of TAM but not the SERM Raloxifene. As we would expect
this gene to be inhibited by TAM, this reveals an added layer of complexity to the
pharmacology of TAM. To investigate this finding further we studied the effects of
compounds which are structurally related to TAM, and found that compounds such as
Endoxifen and 4-Hydroxytamoxifen have similar effects to TAM. To analyse the
sequence requirements for ER induced activation of TGM2 transcription we cloned the
5‟ regulatory region into a luciferase vector. Further study is required in this area to
better understand the significance of TGM2 expression in breast cancer cells.
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1 Introduction
1.1 General Principles of Cell Signalling
Multicellular organisms require elaborate mechanisms of communication
whereby signals from one cell or group of cells influence the behaviour or function of
another group of cells. This can involve direct cell-cell contact in which the signalling
molecule present on the surface of a cell can directly contact a specific protein called a
receptor on the surface on a target cell, initiating a cascade of events that alters the
function of the target cell (Paracrine). The second mechanism of intercellular signalling
involves secretion of a signalling molecule by a cell and the binding of the molecule to
a receptor located either on the plasma membrane or intracellularly in the target cell
(Endocrine) [1].
Signaling molecules may act locally on the same cell (autocrine signalling) or
on neighbouring cells (paracrine signalling) or at a distance as with endocrine
signalling. Because secreted signalling molecules must travel in a hydrophilic
extracellular environment, many signalling molecules are hydrophilic and unable to
cross the plasma membrane. These molecules therefore bind to cell surface receptors
and transmit signals intracellularly. Hydrophilic signalling molecules include proteins,
peptides, amino acids, nucleotides, and certain dissolved gases including nitric oxide
and carbon monoxide. Alternatively, lipophilic signalling molecules, including fatty
acids, steroid hormones, vitamins D3, and retinoids, can diffuse across the plasma
membrane lipid bilayer and bind to intracellular receptors found within the cytosol or
the nucleus. Because these signalling molecules are lipophilic, they travel through the
extracellular milieu bound to carrier proteins. Within the target cell lipophilic molecules
bind to intracellular receptors called nuclear receptors.
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The nuclear receptor superfamily constitutes a family of intracellular receptors
that effect transcriptional programs that play roles in a number of biological processes
by responding to hormonal and metabolic signals.

1.2 Nuclear receptor signalling
1.2.1 The Nuclear Receptor Superfamily
In humans, the nuclear receptor superfamily consists of 49 different receptors
(Figure 1.1). Many nuclear receptors are ligand-activated transcription factors that are
expressed in a cell-restricted manner. Nuclear receptors (NR) can bind a host of
endogenous ligands including steroid hormones, fatty acids, vitamin D3, xenobiotics,
cholesterols, and bile acids, some NRs are orphan receptors whose endogenous ligand
has not been identified.

Figure 1.1 Nuclear Receptor gene family
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Adapted with permission from Prof. D McDonnell, Department of Pharmacology and
Cancer Biology, Duke University, NC.
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Nuclear receptors share a common modular structure that includes 5-6 conserved
domains, A through F (Figure 1.2) [2]. The A/B domain of the receptor is located at the
N-terminus of the protein, and it contains a ligand-independent activation function 1
(AF-1) domain. This domain can activate transcription in an autonomous manner. The
A/B domain is the most variable of the domains and its length varies widely between 23
amino acids for the vitamin D3 receptor (VDR) to over 550 amino acids for the
androgen, mineralocorticoid, and glucocorticoid receptors [3]. The C domain of the
receptor constitutes the DNA Binding Domain (DBD) of the receptor. This domain
confers upon the receptor sequence-specific DNA recognition through two zinc finger
motifs. The D domain of the receptor is a hinge region between the highly structured
domains that precede and follow it.

This domain contains a nuclear localization

sequence, which may play a role in the dynamic nuclear-cytoplasmic shuttling of
nuclear receptors that occurs in response to ligand binding [4]. The E domain of the
receptor is the Ligand Binding Domain (LBD), which is involved in ligand-binding and
dimerisation. The LBD also contains an activation domain called activation function 2
(AF-2), which is a region of the protein involved in recruiting coactivator molecules
that are essential for ligand-dependent transcriptional activity [5]. Some receptors,
including the peroxisome proliferator-activated receptor (PPAR) family possess an F
domain at the very C-terminus [6]. This domain is evolutionarily not well-conserved,
and the roles of the F domain are largely unknown.
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Figure 1.2 Modular structure of nuclear receptors

Reprinted with permission from Prof. D McDonnell, Department of Pharmacology and
Cancer Biology, Duke University, NC.

1.2.2 General Mechanisms of Nuclear Receptor Signalling
In an unliganded-state, nuclear receptors can be localised to either the cytoplasm
or nucleus. Upon ligand binding, nuclear receptors dissociate from any associated heat
shock chaperone proteins to which they are bound, translocate into the nucleus, and
homo- or heterodimerise on specific DNA nuclear receptor response elements (NRREs)
within the promoters of target genes (Figure 1.3). The DNA binding domain, located in
the centre of the protein, contains nine cysteine residues, eight of which can chelate two
zinc molecules, forming two zinc fingers that bind to two adjacent major grooves in the
DNA[7]. Nuclear receptors recognize variations of the hexameric motif 5‟-PuGGTCA
(Pu = A or G) [3]. Some nuclear receptors, including the retinoid acid receptor (RAR),
Vitamin D receptor (VDR), and thyroid receptor (TR) bind to direct repeats of the
hexameric sequence separated by 1-5 nucleotides, termed DR1 through DR5 elements.
The oestrogen receptor prefers a 5‟-PuGGTCA half site sequence, whereas GR prefers a
5‟-PuG(G/A)ACA sequence.
Nuclear receptors regulate gene transcription via several different mechanisms
[8]. Through binding of various ligands, nuclear receptors can repress or activate
transcription by recruiting corepressor and coactivator proteins, respectively [9].
4

Binding of agonist to the nuclear receptor alters the conformation of the AF-2 domain,
facilitating the displacement of corepressors and the recruitment of coactivators. Most
coactivators contain a canonical LXXLL amino acid motif that interacts with the AF-2
of the nuclear receptor. Recruitment of coactivators is essential for nuclear receptormediated gene transcription; their role is to facilitate transcription by remodelling the
chromatin and recruiting RNA polymerase II and the general transcriptional machinery.
Binding of antagonist to the nuclear receptor facilitates the recruitment of co-repressors;
which leads to recruitment of histone deacetylases, condensation of chromatin and
dampening of transcriptional activity.

Figure 1.3 The mechanism of action of intracellular receptors
Cell
Membrane

Nuclear
Membrane

NRRE

Transcription

mRNA

Binding

Translation

Altered
Cell
Function

New Protein

=Ligand

Ligand passes through the cell membrane and binds steroid receptors in the cytoplasm
or nucleus. Binding of ligand induces a conformational change in the receptor structure
permitting dimerisation and binding to specific nuclear receptor responsive elements
(NRRE) in the DNA structure. The recruitment of general transcription activators
(GTA) to the complex allows for the induction of gene transcription and production of a
protein. Adapted with permission from [10].
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1.2.3 Oestrogen Signalling
Oestrogen is probably the most widely studied of all hormones, the term
„oestrogen‟ refers to a group of chemically similar hormones, estrone (E1), estradiol
(E2), and estriol (E3) (Figure 1.4). These hormones are uniquely responsible for the
growth and development of the female sexual characteristics. Estradiol and estrone are
produced primarily in the ovaries in pre-menopausal women, while estriol is produced
by the placenta during pregnancy. Oestrogen acts on cells in a wide variety of tissues
including breast, uterus, brain, bone, liver, and heart to modulate cell activity. For
example, oestrogen controls growth of the uterine lining during the first part of the
menstrual cycle, and cause changes in breast during adolescence and pregnancy and
regulates various other metabolic processes such as bone growth and cholesterol levels.

1.2.4 Oestrogens
Figure 1.4: The structures of the three oestrogens

The three oestrogens, estrone (E1), estradiol (E2), and estriol (E3), are the most
abundant and well-studied endogenous agonists for ER (Figure 1.4). The biosynthesis of
oestrogen in the ovary is initiated in the early follicular stage of the reproductive cycle
in response to follicle stimulating hormone (FSH), a pituitary hormone whose receptor
is expressed in ovarian granulosa cells. Upon receipt of the signal, cholesterol is
mobilized from the outer mitochondrial membrane (OMM) to the inner mitochondrial
membrane (IMM) by steroid acute regulatory protein (STAR). At the IMM, cholesterol
is converted to pregnenolone by the action of the cholesterol side chain cleavage
6

enzyme cytochrome P450 (CYP) 11A1 (CYP11A1).

From there, pregnenolone is

metabolized by numerous CYPs, hydroxysteroid dehydrogenases (HSDs), and
hydroxysteroid reductases to produce oestrogens, as well as other steroid hormones
(Figure 1.5).

Figure 1.5: Steroidogenesis

A diagram of the reactions in the steroidogenic pathway that contribute to the synthesis
of endogenous oestrogens, highlighting the enzymes that catalyze these reactions.
Oestrogens can be metabolized through several mechanisms, including oxidation
by CYPs, sulfation by sulfotransferases, glucuronidation by uridine diphosphateglucuronosyltransferases (UGT), and O-methylation by catchol O-methyltransferases
(COMT) (Figure 1.6) [11]. The primary site of E2 metabolism is the liver, where
CYP1A2, CYP3A4, and CYP1B1 mediate 2 – and 4-hydroxylation of E2. Outside the
liver (in the breast, uterus, placenta, brain, and pituitary) CYP1A1, and to some extent
CYP3A4, converts E2 to the 2-hydroxylated form.

COMT rapidly methylates 2-

hydroxy-E2 to avoid free radical formation and is thus considered to be anti7

tumourigenic. In the breast and uterus, CYP1B1 actively produces high levels of 4hydroxy-E2. Unfortunately, 4-hydroxy-E2 is rapidly converted between semiquinone
and quinone forms, which generate free radicals that cause DNA damage, and thus
CYP1B1 metabolism of E2 is considered genotoxic. There is evidence to suggest that
E2 can control the expression of its metabolic enzymes, although the data is not clear
[11]. Oestrogens function through ER to control particular biological processes, as
discussed below.

Figure 1.6 Oestradiol Metabolism

The creation and metabolism of E2 is catalyzed by many members of the CYP family.
E2 metabolites fall into two main categories, those that are genotoxic and those that
may inhibit tumourigenesis [11].

8

1.2.5 The Oestrogen Receptor
ER is a member of the nuclear receptor (NR) super-family of ligand-activated
transcription factors. There are two genetic subtypes of ER, ER and ER, which
exhibit overlapping but distinct activities and expression patterns [12-15]. They share
the same modular structure: an N-terminal A/B domain, the C domain containing the
zinc-finger DNA binding domain (DBD), a hinge region (D domain), the E domain
which houses the ligand binding domain (LBD), and the C-terminal F domain (Figure
1.7). Given their high degree of homology in the LBD and DBD, it is not surprising
that ER and ER regulate mostly identical DNA response elements and bind many of
the same endogenous and exogenous ligands [14, 16]. Tissue distribution patterns and
knockout mouse models of ER indicate that ER and ER are not redundant, and
instead suggest unique tissue-specific functions for each receptor subtype [12, 17].
ER is more ubiquitously expressed throughout the body, whereas the pattern of ER is
restricted to the testis, ovary and thymus [12]. Together, ER and ER control many
important biological processes, including ovulation, mammary gland development,
proper bone mineral density, cardiovascular function, aspects of mating behaviour, and
the immune system [17].

9

Figure 1.7 Schematic of ER structure

Schematic illustration of ER modular structure, highlighting the amino acid similarity
between ER and ER. Adapted with permission from [18].

Residing in either the cytoplasm or nucleus, signalling through ER is initiated by
either ligand binding or by ligand-independent processes such as phosphorylation. The
transcriptional activity of ER is mediated by the activation functions (AFs), of which
there are two in ER (AF-1 and AF-2) but only one in ER (AF-2). AF-2 is located
within the LBD and is primarily responsible for ligand-dependent activation of
transcription, whereas AF-1 is thought to transduce ligand-independent transcriptional
activation.

When both are present, as in ER, AF-1 and AF-2 can function

synergistically or independently, depending on cell and promoter context, thus adding a
layer of complexity [19]. The distinct biologies of ER versus ER may stem from the
divergent A/B and F domains, particularly since no obvious AF -1 domain is found in
ER.
1.2.5.1 Activation of transcription
To activate transcription, the general transcriptional machinery must be recruited
to DNA.

Although it was once considered that ER directly interacted with this

machinery, it is now apparent that the protein-protein interaction surfaces on ER recruit
coregulatory proteins, such as coactivators and corepressors, which bridge this
10

interaction (Figure 1.8). Coregulatory proteins interact primarily with ER at the AF-2
domain, where a hydrophobic pocket is formed predominantly by helix 12 (H12)
(Figure 1.9)
Figure 1.8 Diagram of ER agonist and antagonist activity

The binding of agonist to the ER induces a conformational change in the receptor
structure which facilitates dimerisation and recruitment of coactivators to the receptor
complex. This allows for the activation of transcription of E2 regulated genes. The
binding of agonist to the ER facilitates dimerisation and recruitment of corepressors
which does not lead to gene transcription. Corepressor (CoR), coactivator (CoA).
Adapted with permission from [20].

Figure 1.9 Structure of the nuclear receptor/coactivator complex

The interaction of ER AF-1 and AF-2 with coactivator (CoA). Adapted with permission
from [20].
11

This pocket binds the hydrophobic sequence LxxLL found in coactivators. [21]
Coactivators can promote transcription through several mechanisms: the acetylation of
histones by steroid receptor coactivators (SRC) -1, -2, and -3, thyroid hormone receptor
activating protein of 220kDa (TRAP220), and CREB-binding protein (CBP/p300); the
methylation of histones by protein arginine methyltransferase 1 (PRMT1); RNA
processing by RNA helicases such as p68; and the coupling of ER to degradation
machinery through the ubiquitin ligases E6-associated protein and ribosome production
factor 1. [22-23] The other class of coregulatory proteins, the corepressors, contain a
similar domain, the CoRNR box motif, that binds to the hydrophobic pocket in ER [24].
In general, corepressor proteins either recruit or exhibit intrinsic histone deacetylase
activity, thereby actively repressing transcription (Figure 1.10).

Figure 1.10 ER-associated cofactors

Diagram showing coactivators (+), corepressors (-) and other associated proteins.
Oestrogen receptor shape influences cofactor binding preferences [10]. Adapted with
permission from [25].
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After binding to ligand, ER undergoes a conformational change that is critical in
dictating the downstream biological response. Previously, it was thought that there
were only two conformations that ER could adopt; an active and an inactive one.
However, the discovery that different ligands confer unique responses made this model
unlikely. Instead, it appears that each ligand induces a unique conformational change
that allows for differential presentation of protein-protein interaction surfaces that are
used to couple ER to other signalling pathways, therefore determining the cellular
response to a particular ligand [26].
After binding to oestrogen and undergoing a conformational change, ER
dimerises and binds to DNA within the regulatory regions of target genes [27]. Direct
ER binding to DNA occurs at oestrogen response elements (EREs), whereas ER can
also interact indirectly with DNA through binding to Fos and Jun at AP-1 (activator
protein 1) elements [28] or to specificity protein 1 (Sp1) family members at GC-rich
DNA regions [29]. The specific ERE sequences influence the affinity of ER binding by
inducing a unique conformation in the ER structure which may contribute to the
promoter specific activities of the ER on different ERE-containing genes [30]. The
canonical

ERE

was

determined

to

have

the

consensus

sequence

5‟-

GGTCAnnnTGACC-3’ [31-32]. The symmetry of the sequence facilitates the binding of
ER as a homodimer [33]. However, only a handful of the most highly oestrogenresponsive genes actually contain perfect consensus EREs. Many genes have been
found to contain sequences that appear to be EREs, but most of these vary from the
consensus by one or more nucleotides. Studies of ER binding showed that one or more
changes from the consensus sequence resulted in lower ER-ERE affinity and that
sequences immediately flanking the ERE impact ER-ERE binding [34]. One study has
performed a genome-wide analysis of oestrogen receptor binding sites, identifying a set
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of 3665 unique ER binding sites. This study has shown that the percentage of
upregulated genes in breast tumours with an ER binding site within 100kb is 56 - 59%.
Also almost one-third of early-oestrogen upregulated genes have ER binding sites
within 50kb of the transcription start site [35], while there at least 236 genes with a
consensus ERE within -10 to +5 kb of the 5‟ end [36].
Besides binding ERE sequences on the gene promoter, ERα or ERβ can activate
transcription through different types of DNA enhancer elements such as AP-1 sites.
This requires ligand-bound ER and the AP-1 transcription factors Fos and Jun. ERα or
ERβ both have different transactivation behaviour at Ap-1 sites.
After initiating transcription, ER undergoes ligand-mediated degradation
through the 26S proteosome. The activity of particular coactivators, such as AIB1
(amplified in breast cancer 1), has been shown to be necessary for ER degradation
under certain contexts [37], therefore bringing forth the hypothesis that DNA-bound
ER recruits the proteins that target it for destruction. The complete identity of these
proteins, and whether they interact with ER in the same way as coactivators, has yet to
be fully elucidated. Further, ER does not undergo ligand-dependent degradation,
despite efficient transcription, suggesting perhaps that another surface outside the
coactivator binding groove may be responsible for recruitment of the degradation
machinery.
Besides its well-studied role in modulating transcription of target genes, ER may
also regulate other biological processes in both the nuclear and cytoplasmic
compartments through both ligand-dependent and –independent mechanisms. These
include association with the phosphotidylinositol-3-kinase (PI3K), insulin-like growth
factor 1 (IGF-1), and extracellular signal-regulated kinase/mitogen-activated protein
kinase (ERK/MAPK) pathways. IGF-1, like E2 is a potent mitogen which is involved in
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a large array of processes that control proliferation and differentiation in mammalian
cells. One study has shown that E2 activates IGF-1 receptor and ERK1/2 via ERα
leading to activation of the IGF-1 signalling cascade [38-40]. Activation of IGF-1
receptor leads to the selective recruitment of downstream signaling molecules and
results in activation of the Ras/Raf/MAPK signaling cascade. Phosphorylation of ERα
at serine 118 is required for full action of AF-1, as ER activation by growth factors
involves the MAPK pathway; this is another potential interaction site of the two
pathways [41]. This cross-talk between IGF-1 receptor and ER signalling pathways
results in synergistic growth stimulation.
It has also been established that oestrogens induce rapid increases in cAMP as
well as activation of phospholipase C [42]. The time course of these acute events
supports the hypothesis that they do not involve the „classical‟ gene activation action of
oestrogens. Through interaction with these pathways, ER activity can be regulated by
direct phosphorylation or by phosphorylation of its coactivator and corepressor proteins.
The exact role of these phosphorylation events, and other potential posttranslational modifications, on the signalling competency of ER and its coactivators
remains to be fully elucidated. These pathways may play a pivotal role in oestrogenindependent breast cancer cell growth and tamoxifen-resistance.
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1.3 Breast Cancer
1.3.1 General information
In 2007 there were 2463 new cases of breast cancer in Ireland, the number of
new cases has been rising steadily each year (+2.4%). However mortality rates have
dropped by about 2% per annum (1994-2004), likely due to increased early detection,
better therapeutics, and successful prevention strategies. Breast cancer is the most
common cause of cancer death in women, at over 660 deaths per year (National Cancer
Registry).
Breast cancer is a malignancy of the epithelial cells comprising the mammary
gland. Many risk factors have been identified for breast cancer, including lifetime
exposure to endogenous hormones, obesity, increased age, family history, and alcohol
consumption. The primary treatments for breast cancer are surgery, radiation therapy,
and

systemic

chemical

therapy,

which

include

chemotherapeutics

and

endocrine/hormone therapy.

1.3.2 The role of oestrogen and ER in breast cancer
Oestrogens and ER have been implicated in many cancers, but none so clearly as
breast cancer. In 1896 it was first suggested that ovariectomy induced regression of
metastatic breast cancer [43], and by 1900 it became clear that this surgery had a onethird response rate in metastatic breast cancer [44]. The discovery of oestrogen in
ovarian follicular fluid set the stage for the development of compounds that either
mimic or inhibit classic oestrogenic responses [45]. Breast cancer cells may be either
positive or negative for the ER; most ER positive breast cancer cells require the ER for
growth and survival. ER positive breast cancers exhibit stronger clinical responses to
hormonal treatment and have a more differentiated morphologic appearance [46-47].
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In mammary epithelial cells, E2 signalling through ER promotes cellular
proliferation, which when unchecked can lead to pathologic disease. Even after
menopause, when systemic E2 production is largely decreased, adipose tissues continue
to make E2 and many breast tumours acquire the ability to locally produce E2 through
expression of the aromatase enzyme (CYP19) [48-49]. In addition to promoting cell
proliferation, E2/ER engages the ERK/MAPK and PI3K signalling pathways to
increase cell proliferation and survival. As discussed earlier, some metabolites of E2 are
DNA damaging agents that may increase DNA mutagenesis, leading to increased
probability of cell transformation [49-50].

1.3.3 Breast Cancer pharmacology
Given the implication of E2/ER signalling in the aetiology of breast cancer,
pharmaceutical efforts have uncovered many natural and synthetic modulators of ER
activity and E2 synthesis with a wide range of activities. The Selective ER Modulators
(SERMs) are characterized by three important qualities: they bind competitively to ER,
they induce a unique conformational change in ER that facilitates differential cofactor
interactions, and they exhibit promoter- and tissue-specific activity (Figure 1.10).
SERMs allow the ER to adopt a structure which is intermediate between that observed
following the binding of agonist or antagonist, which may or may not lead to gene
transcription.
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Figure 1.11 ER activation complex showing the selective nature of Tamoxifen in
different cells.

A

B

The activities of AF-1 and AF-2 are manifested in a cell-specific manner. (A) In some
cells the interaction of both ER-AF domains with a cellular cofactor is required for
transcriptional activity. In these cell contexts, estradiol (E2), but not tamoxifen,
functions as an agonist. (B) In other cell contexts, ER-AF-1 alone is required for ER
transcriptional activity. Therefore Tam is an AF-1 agonist. Reprinted with permission
from [51].
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Tamoxifen (TAM) and raloxifene (RAL) are SERMs that have clinical utility in
breast cancer (Figure 1.12), and the tissue-specific activity profiles of these compounds
as compared to E2 are shown in Table 1.1. In the context of the breast, both TAM and
RAL are considered ER antagonists based on their ability to block coactivator
recruitment to ER and thus transcriptional activation, yet they have different biological
consequences as assessed by their individual abilities to decrease the risk for either
invasive or non-invasive breast cancer. Whereas TAM decreases the risk for both
invasive and non-invasive breast cancer, RAL only decreases the risk for invasive breast
cancer, suggesting perhaps that differences exist in their mechanism of action in the
breast [52]. Raloxifene has been shown to decrease the risk of invasive breast cancer by
76% during 3 years of treatment. This was attributable to a 90% reduction in the risk of
ER-positive breast cancer, while there was no apparent decrease in the risk of ERnegative breast cancer [53]. A distinction between TAM and RAL is highlighted in the
uterus, wherein TAM is an ER agonist and thereby increases the risk for
endometrial/uterine cancer and endometriosis, but RAL is an ER antagonist [54].
Therefore SERMs display tissue-selective pharmacology, acting as an agonist in some
tissues and antagonists in other tissues. Also E2, TAM, or ICI (ICI 182,780) bound ERα
will all activate transcription through AP-1 whereas only TAM or ICI bound ERβ
activates transcription through Ap-1 [55]. This reveals a potential control mechanism
for transcriptional regulation of E2-responsive genes and also adds a layer of
complexity to the differential pharmacology of TAM
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Figure 1.12 Structures of Tamoxifen and Raloxifene

Reprinted with permission from [51].

Table 1.1: The relative agonist activities of SERMs

The relative activities of E2, Tamoxifen and Raloxifene in various cell types. [52-53]

The active form of Tamoxifen, 4-Hydroxytamoxifen (4OHT), has been shown to
be exhibit 30 to 100-fold higher potent anti-oestrogenic activity than that of Tamoxifen
[56]. For this reason Tamoxifen is often referred to as a pro-drug that requires
conversion to its hydroxylated metabolite to exert its activity. The secondary metabolite
of 4OHT, Endoxifen (4-hydroxy-N-desmethyl-tamoxifen), is as potent as 4OHT with
respect to ER binding and inhibition of E2 induced cell proliferation. Endoxifen is
formed by the cytochrome P450 2D6 (CYP2D6) and has been shown to be present in a
6 fold higher concentration than 4OHT in patients receiving Tamoxifen. Therefore this
may suggest that Endoxifen could be a more important contributor to Tamoxifen
activity than 4OHT [57].
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Bazedoxifene is a SERM which is currently under development by Wyeth
Pharmaceuticals for the prevention and treatment of osteoporosis. Bazedoxifene is
shown to transactivate the ER, and positively affect the skeletal and lipid profile without
stimulating the uterine endometrium, causing breast cancer proliferation, or negatively
impacting the central nervous system [58]. Lasofoxifene is a nonsteroidal SERM which
is currently under development by Pfizer for the prevention and treatment of
osteoporosis and vaginal atrophy. Lasofoxifene binds ERα and ERβ selectively (100
fold selectivity against all other NRs) and with high affinity [59].
Another class of ER ligands that has been developed clinically is the selective
ER down-regulators (SERDs), which include ICI and GW5638. SERDs, similar to
SERMs, bind competitively to ER, but have the additional activity of inducing rapid recompartmentalisation and degradation of ER protein. This activity contributes to the
efficacy of SERDs such as ICI as a second-line therapy for patients who have failed at
least one endocrine therapy, such as in Tamoxifen-resistant breast cancer. GW5638 has
been shown to function as oestrogen in skeletal and cardiovascular systems while
opposing the actions of oestrogen in the breast and uterus. Importantly, it also inhibits
the growth of tumours that are resistant to (or stimulated by) Tamoxifen.
Besides inhibiting ER signalling at the level of ligand binding, another way to
impact ER signalling is to reduce the concentration of its agonist, E2. As mentioned
above, E2 synthesis from testosterone requires the aromatase enzyme, which also
catalyzes the conversion of androstenedione to E1. Thus, aromatase inhibitors (AIs),
such as anastrozole, exemestane, and letrozole, have been developed [60]. However,
only 40 – 50 % of patients respond to AIs, suggesting de novo or acquired resistance
mechanisms of circumventing this particular block in E2 synthesis. One hypothesis is
that breast tissue expresses high levels of steroid-sulfatase expression, which converts
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E1-3-sulfate into the un-sulfaconjugated form, whereby subsequent action of 17-HSD
creates E2 [61]. Other rationales maintain that perhaps not all ER-positive breast
cancers rely on E2 and may instead rely on other endogenous oestrogenic compounds
[62], or that distinct molecules and signalling pathways, such as the epidermal growth
factor receptor (EGFR)/MAPK pathway [63], compensate in the face of an AI to
continue to induce cell proliferation and survival.
The addition of targeted therapies to traditional chemotherapeutic regimens has
provided significant benefit with relatively mild side effects. For example, treatment of
early-stage ERα positive breast cancer with Tamoxifen, results in a 30% reduction in
annual mortality. Use of an aromatase inhibitor, such as Letrazole, shows comparable
benefit with an improved side effect profile; the most serious common side effect,
cardiovascular events, occurs in less than 1% of patients. The success of anti-oestrogen
therapies in the treatment of breast cancer highlights the importance of E2 and ER in
the development and progression of this disease, but both de novo and acquired
resistance suggest that there is still much to learn. A more thorough understanding of
the signalling pathways and how they interact and intersect will allow for the
development of superior targeted therapies as well as better biomarkers that predict risks
and likelihood of response to a given therapeutic.

1.3.4 Breast cancer cell lines as in vitro models
The study of breast cancer cell lines powerfully informs both our molecular
understanding of this disease and the development of novel therapeutic agents. Current
research aims to closely analyse tumour heterogeneity and tumour-stromal interactions
in in vitro models of cancer. The majority of the breast cancer cell lines were derived
from metastatic tumours as the highly malignant nature of these cells facilitates their
long-term proliferation. Three cell lines that were developed in the 1970‟s (MCF-7, T22

47D and MDA-MB-231) were used in the vast majority of published breast cancer
studies. However there are some disadvantages in using cell lines as these are prone to
genotypic and phenotypic drift during their continual culture. One study highlighted
many discrepancies in MCF-7 cells obtained from different laboratories, demonstrating
variations in cell growth rate, hormone receptor content, karyotype and clonogenicity
[64]. Another pitfall of using these breast cancer cell lines is that most of these cells are
derived from tumour metastasis rather than the primary legion. Thus research based on
such cell lines will be biased towards more rapidly progressive types of breast cancer
and to late stage disease rather than lower grade and earlier stage breast cancer. An
alternative to using cell lines is to prepare primary cultures derived directly from a
breast tumour which has the advantage of being able to compare the characteristics of
the culture with those of the original tumour. However primary cultures have slow
population doubling times and a finite lifespan also these cells may behave differently
in culture compared to their response when they are part of a tissue/organ. Because of
the ease of use of cell lines they remain the model of choice for breast cancer research,
however it is important to understand their limitations and take these into consideration
when designing experiments and interpreting results.
The general attributes of breast cancer cell lines (such as ER positive or
negative) necessarily informs the choice of a particular cell line in the experiment as
well as the interpretation of experimental results [65]. MCF-7 cells are used in the
majority of the experiments in this study as these cells express ERα but do not express
ERβ.
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1.4 Tissue Transglutaminase
1.4.1 Physiological Functions
Tissue or type 2 transglutaminase (TG2,1 EC 2.3.2.13) is a ubiquitously
expressed multifunctional enzyme belonging to the transglutaminase family which is
coded by the TGM2 gene [66]. Tissue Transglutaminase protein (referred to as TG2) is
a 687 amino acid protein and 77329 Da in size. Its primary function is catalyzing the
Ca2+ -dependent acyl transfer reactions between carboxamide groups of glutamine
residues and amino groups in lysine residues in peptides, forming cross-links in
proteins. Transglutaminases are expressed in a variety of tissues and differ in their
pattern of expression, substrate specificity and their physiological regulation. Some
members of the transglutaminases such as Factor XIIIa, which is involved in blood
clotting, are secreted from the cell and are involved in cross-linking of plasma proteins.
Other transglutaminases, such as keratinocyte transglutaminases, are intracellular
enzymes which play a major role in cross-linking proteins in the differentiation and
cornification of skin cells [67]. Tissue transglutaminase (TG2) is an intracellular
transglutaminase which may be secreted from the cell where it is involved in processing
the matrix that occurs during osteogenesis, wound healing and other remodelling
processes [68]. However the enzyme‟s method of secretion is not fully understood. Like
Factor XIII and several other extracellular proteins, tissue transglutaminase does not
contain a leader peptide or obvious secretory signal and it remains to be determined how
the enzyme becomes deposited in the extracellular compartment. One study has shown
that increased expression and activation of TG2 leads to increased externalisation of the
protein, whereas inactive TG2 was not externalised. This study also showed that
exposure of the active site is key in determining enzyme secretion [69].
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Evidence also exists to show that TG2 has a role in apoptosis, where both high
levels of the protein synthesis and enzymatic activity are observed. Activation of TG2
crosslinking activity during both physiological and pathological apoptosis leads to
assembly of an intracellular protein scaffold contributing to the stabilization of dying
cells, before their clearance by phagocytosis. TG2 therefore stabilizes the integrity of
the apoptotic cells, preventing the release of harmful intracellular components into the
extracellular space. In non-apoptotic cells the binding of GTP prevents the activation of
TG2, allowing the cell to survive in the presence of high TG2 protein levels [70].
During apoptosis the drop in intracellular GTP and an increase in Ca2+ lead to the
activation of TG2. Cell surface-bound Tissue Transglutaminase is also thought to be
involved in cell adhesion and cell migration processes by a mechanism independent of
its cross linking activity [71].

1.4.2 Oestrogen Receptor control of TGM2 expression
It has been previously shown that E2 activates the TGM2 gene in cells which
contain either ERα or ERβ. This ER-induced activation is inhibited by ICI 182780 [72].
It is thought that the ER activates TGM2 through an ERE located in its promoter. The
proximal TGM2 promoter contains an 8/10 match with the canonical ERE
(GCGGTCAAGG CTACCTG) (Figure 1.13).
As discussed earlier the ER may also mediate gene transcription from an AP1
enhancer element that requires ligand and the AP1 transcription factors Fos and Jun for
transcriptional activation. The TGM2 promoter contains a 6 out of 7 match to the
canonical AP-1 site (TGAGCA) (Figure 1.13).
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Figure 1.13 TGM2 5’ flanking region with putative ERE and AP-1 sites

CpG Island

Diagram of TGM2 5‟ flanking region showing putative ER binding sites, CpG
methylation site, translation start site and transcription start site.
The proximal promoter of this gene includes two CpG-rich regions, well
recognised sites of DNA methylation. These sites are concentrated in two clusters of
CpG dinucleotides; one is located in the core promoter (nucleotides -205 to +75)
(Figure 1.13) and the other is located approximately 1.3kb upstream. One study has
shown that methylation of the proximal CpG region results in a marked decrease in
transcriptional activity while demethylation increases transcription [73]. This study
describes a mechanism for the negative regulatory control of TGM2 by DNA
methylation. Release from the inhibition of this regulatory mechanism may play an
important role in controlling the level of transglutaminase expression in a tissue-specific
manner.

1.4.3 Role of TG2 as a tumour suppressor
The growth and development of new tissue in physiological and pathological
conditions relies on the generation of new blood supply. The control of inappropriate
angiogenesis in diseases such as cancer has been a keen area of research, leading to the
development of novel anti-angiogenic agents. While some of the functions of TG2
protein are similar to those required for angiogenesis, the role of TG2 in this process is
poorly understood. It has been shown that TG2 is down-regulated in epithelial cells
undergoing capillary angiogenesis; also TGM2 gene knock-out mice show no vascular
abnormalities [74]. These findings fit in with the proposed role of TG2 in extracellular
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matrix stabilisation, since angiogenesis requires local destabilisation of the matrix. One
study has shown that application of exogenous TG2 blocks angiogenesis in a dosedependent manner without causing cell death. The same study also shows that
intratumour injections of TG2 inhibited tumour growth and increased survival in mice
bearing carcinoma tumours. Also tumours grafted into TGM2 knockout mice (TGM2-/-)
showed a significant increase in tumour growth compared to TGM2+/+ mice [75].

1.4.4 TG2 in chemotherapy resistant breast cancer
Chemotherapeutic drugs such as Doxorubicin are used in the treatment of breast
cancer. This drug is known to intercalate DNA thus preventing transcription; it also
inhibits the topoisomerase type II enzyme stopping the process of replication.
Resistance to chemotherapy is a major obstacle to successful treatment of breast cancer.
Although chemotherapy drugs are outside the focus of this study, the implications of
TG2 protein in drug resistance is relevant. A direct link has been established between
the development of drug resistance and metastatic phenotypes in breast cancer and
increased expression of TG2. One study demonstrated that TG2 protein expression is
up-regulated in drug-resistant and metastatic breast cancer cells, and it could serve as a
prognostic marker for the development of these phenotypes [76].
As discussed earlier, many reports have supported the involvement of TG2 in
apoptosis; its overexpression primed cells for apoptosis whereas its inhibition by
antisense RNA rendered the cells resistant to induction of apoptosis [77]. Contrary to
this, recent evidence indicates that increased expression of TG2 may prolong cell
survival by preventing apoptosis [78]. It has been proposed that pro-apoptotic and antiapoptotic effects of TG2 strongly depend on its location within the cell. One study has
shown that cytosolic TG2 is pro-apoptotic while nuclear TG2 diminishes apoptosis [79].
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It has been shown that TG2 protein levels in drug-resistant tumour cells is about
10 times higher than that in drug-sensitive tumour cells [80]. However it is thought that
these cells are to be able to survive in the presence of high TG2 due to deficient
intracellular calcium levels [81].

1.4.5 Structure of TGM2 gene
The TGM2 gene is composed of 13 exons covering a size of 35kb on the long
arm of chromosome 20 (20q12) which is expressed as a 3.6kb mRNA in human
endothelial cells (Figure 1.14) [82].
Figure 1.14 Layout of exons in TGM2

Diagram of TGM2 exons drawn to scale.
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2 Aims
The aim of this study was to investigate the differential promoter-specific
pharmacology of Tamoxifen (TAM) in the context of breast cancer cells using TGM2 as
a model. We analysed the effects of SERMs which are structurally and functionally
related to TAM. We also aimed to compare the inhibitory activities of TAM on a group
of ER regulated genes in various breast cancer cell types. To this end we cloned the
sequence upstream of the TGM2 gene promoter containing the putative nuclear receptor
response elements and insert it into a luciferase plasmid for use in transient transfection
assays.
Specifically we aimed to:


Study effects of Tamoxifen and Endoxifen on TGM2 mRNA expression



Analyse the requirements of ER or other cellular factors in TGM2 activation



Search the TGM2 5‟ flanking region for possible ER binding sites



Clone a sequence from this 5‟ region into a luciferase vector



Determine the degree of transcriptional regulation of the isolated TGM2
promoter region by ER and E2/TAM
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3 Materials and Methods
3.1 Materials
3.1.1

Materials used for cell culture



Cell culture dishes (100 x 20mm): BD Falcon (Franklin Lakes, NJ ) (cat. 353003)



Cell culture plates (12 well): Corning Incorporated (Corning, NY) (cat. T-2989-6)



Dulbecco‟s Modified Eagle Medium (DMEM): Invitrogen (Carlsbad, CA), Nutrient
Mixture F-12 Ham 1X (DMEM/F12 1:1) (cat. 11330) Lot number: 488586,
supplemented with 8% charcoal stripped fetal calf serum, 0.1 mmol/L nonessential
amino acids and 1 mmol/L NaPyr.



DMEM (Phenol red free): Invitrogen Gibco, Nutrient Mixture F-12 Ham 1X
(DMEM/F12 1:1) (cat. 21041) Lot number: 495171, supplemented with 8%
charcoal stripped fetal calf serum, 0.1 mmol/L nonessential amino acids and 1
mmol/L NaPyr.



RPMI 1640 (Invitrogen Gibco): supplemented with 8% fetal bovine serum (FBS)
(Hyclone Laboratories), 1 mM sodium pyruvate, and 0.1 mM non-essential amino
acids (Invitrogen) (cat.10-040-CV) Lot number: 10040424



RPMI 1640, Phenol red free (Invitrogen Gibco): supplemented with 8% fetal bovine
serum (FBS) (Hyclone Laboratories), 1 mM sodium pyruvate, and 0.1 mM nonessential amino acids (Invitrogen) (cat. 11835) Lot number: 492502



Minimum Essential Media (MEM): Invitrogen Gibco supplemented with 8% fetal
bovine serum (FBS) (Hyclone Laboratories), 1 mM sodium pyruvate, and 0.1 mM
non-essential amino acids (Invitrogen) (cat.11095) Lot number: 539196



MEM (phenol red free): Invitrogen Gibco supplemented with 8% fetal bovine serum
(FBS) (Hyclone Laboratories), 1 mM sodium pyruvate, and 0.1 mM non-essential
amino acids (Invitrogen)
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Oestradiol (E2): obtained from Sigma Aldrich (St. Louis, MO)



Trypsin: Sigma– (0.25% Trypsin – EDTA solution) Lot number: 8J0422



100% Ethanol: Pharmaco-AAPER (Brookfield, CT)



Dimethyl-sulphoxide (DMSO): Sigma Lot number: 25K2409



Tamoxifen (TAM), 4-hydroxytamoxifen (4OHT) obtained from Sigma Aldrich



ICI 182,780 (ICI) obtained from Tocris Bioscience (Ellisville, MI)



Endoxifen obtained from Ross Weatherman, Purdue University



Bazedoxifene, Lasofoxifene and Raloxifene obtained from Wyeth (Madison, NJ) as
a donation to research.



α-Napthoflavine, β-Napthoflavine obtained from Sigma Aldrich



All Trans Retinoic Acid (ATRA) obtained from Sigma Aldrich (cat. R2625)



Interleukin – 6 (Il-6) obtained from Sigma Aldrich (cat. I3268)



50ml tubes: Greiner Bio-One (Monroe, NC) (cat. 227261) Lot number: 08420195



TE buffer: (10mM Tris & 1mM EDTA)



PBS: Cellgro (Manassas, VA) Dulbeccos Phosphate Buffered Saline (cat. 21-031CV) Lot number: 21031303



Cells: MCF-7, MDA 231, BT483, HeLa and Skbr-3 obtained from American Type
Culture Collection (ATCC, Manassas, VA)
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Cell lines used in this study, all of which are epithelial tumour cells, are shown
below:

Table 3.1 Human cell line used in current study
Cell line



ATCC No

Attributes

MCF-7

HTB-22

ER positive, breast

MDA-MB-231

HTB-26

ER negative, breast

BT483

HTB-121

ER positive, breast

Skbr-3

HTB-30

ER negative, breast

HeLa

CCL-2

ER negative, cervical

pRST7-ERα expression plasmid (Accession no. X03635)

3.1.2 Materials used for RNA isolation


2-Mercaptoethanol: Sigma Lot number: M3148



DEPC water: Omnipur Lot number: 1108B425



RNA isolation kit: Bio-Rad (Hercules, CA) Aurum Total RNA Minikit (cat. 7326820) Lot number: 7326820

3.1.3 Materials used for Reverse Transcriptase (RT) PCR


Isolated RNA



Spectrophotometer: Beckman (Fullerton, CA) DU640



PCR Tubes and Strip Caps (8 Strip): Phenix (Candler, NC) (cat. MPX-445) Lot
number: 080930-800



cDNA Synthesis Kit: Bio-Rad iScript (cat.170-8890) Lot number: 92079967



Bio-Rad iCycler
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3.1.4 Materials used for Quantitative PCR


cDNA samples



qPCR plates: (96 well) Bio-Rad



Bio-Rad Microseal „B‟ Film (cat. MSB1001)



Sybr Green supermix: Qiagen (Valencia, CA)



Bio-Rad iCycler optical system with associated software

Table 3.2 qPCR primers used for qualitative analysis of mRNA
Forward (5’-3’)

Reverse (5’-3’)

36B4

GGACATGTTGCTGGCCAATAA

GGGCCCGAGACCACTGTT

TGM2

TCACCTTCAGTGTCGTGACC

TCCTCTTCCGAGTCCAGGTA

RET

GGATTAAAGCTGGCTATGGCA

TGGCTTGTGGGCAAACTTGTG

pS2

TCCCCTGGTGCTCTATCCTAATAC

GCAGTCAATCTGTGTTGTGAGCC

WISP2

CCTACACACACAGCCTATATC

CCTTCTCTTCATCCTACCC

CYP1A1

TGCAGAAGATGGTCAAGGAG

AGCTCCAAAGAGGTCCAAGA

36B4 qPCR primers span exons 4 & 5, TGM2 primers span exons 2, 3 & 4, RET
primers span exons 9 & 10, pS2 primers span exons 2 and 3, CYP1A1 primers span
exons 2 & 3.

3.1.5 Materials used for PCR of genomic DNA


DNA isolation: Qiagen DNeasy kit (cat. 69564) Lot number: 42151724



MCF-7 cells



Isolated DNA



Cloned Pfu Turbo: Stratagene (La Jolla, CA) (cat. 600153) Lot number:
0006037068



Pfu buffer (10X): Stratagene (cat. 600153.82) Lot number: 0650189



PCR grade water
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GC-rich PCR: Clontech (Mountain View, CA) Advantage GC kit (cat. 639114) Lot
number: 8051025



dNTPs (50X)



Agarose: Omnipur lot. 0265B068



TAE buffer



Electrophoresis chamber



Ethidium Bromide solution: Bio-Rad– (10mg/ml) (cat. 161-0433)



DNA ladder (1kb): Bio-Rad (cat. 170-8204) ) Lot number: L1708204



DNA ladder (100bp) GIBCO BRL (cat. 15628-019) Lot number: 1082294



Primers obtained from Sigma Aldrich (designed with a 5‟ XhoI binding site) as
shown in Table 3.3
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Table 3.3 Sequences of primers targeting regions of TGM2 gene
Forward-1645

5‟-ATCGCTCGAG GAGCAGTTTCTGCAACAATC-3‟

Forward -900

5‟-ATCGCTCGAG GTCTGTTTTTGCAGGTGTGT-3‟

Forward -561

5‟-ATCGCTCGAG GCCAGCCGTGTTTGGTG-3‟

Reverse +50

5‟-ATCGCTCGAG CCACTGGCGGCGAGAC-3‟

Reverse -305

5‟-ATCGCTCGAG CCCTCATAGAAACACACAACG-3‟

Reverse -540

5‟-ATCGCTCGAG CCACAGTTACACCAAACACG-3‟

F-690

5‟-ATCGCTCGAG TCTGGACACCTGCTCATCTG-3‟

R-480

5‟-ATCGCTCGAG GCAGACACACCAAGACAGGG-3‟

F-1200

5‟-ATCGCTCGAG GGCTGCTATGGTCATTTCC-3‟

R-exon9

5‟-ATCGCTCGAG GTCCCTGGCAGAGGTAGAAA-3‟

F+exon9

5‟-ATCGCTCGAG GGGTATGTGCCCTCAGAGTCTT-3‟

R+700

5‟-ATCGCTCGAG GGGCTAAGGCTGTGTTTTACT-3‟

F-UBS

5‟-ATCGCTCGAG GGCTTTGAGATTGGACTGC-3‟

R-UBS

5‟-ATCGCTCGAG GGCCTGGACTTAGTTCATTACA-3‟

F_UBS-560

5‟-AACCCTCGAG GTGGTAGGAACAAAGCCATTG-3‟

R_UBS+550

5‟-AACCCTCGAG CACCAGCTCCATTCTGAACA-3‟

F_ERE-1120

5‟-GGAACTCGAG CTGTGAGGGAGGGATTCTTT-3‟

R_ERE+440

5‟-GGAACTCGAG CGGACAGGGACACACAACTA-3‟

All primers have an XhoI binding site motif (CTCGAG) (in red) with a 4 bp spacer (in
blue) tagged to the 5‟ end. Primers are named by the distance in bp to their relevant
putative ER binding region; either within the 5‟binding region, 3kb upstream or within
exon 9. (F, Forward; R, Reverse; UBS, upstream binding sequence)
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3.1.6 Materials used for cloning of DNA fragments


PCR purification kit: GeneScript (Piscataway, NJ) (cat. L00198) Lot number:
PP00107



DNA extraction kit: GeneScript gel (cat. L00199) Lot number: GE00107



XhoI restriction enzyme: New England Biolabs (Ipswich, MA) (cat. R0146S) Lot
number: 54



HindIII restriction enzyme: New England Biolabs (cat. R014S) Lot number: 66



BglII restriction enzyme: New England Biolabs (cat. R0144S) Lot number: 40



KpnI restriction enzyme: New England Biolabs (cat. R0142S) Lot number: 51



SacI restriction enzyme: New England Biolabs (cat. R0156S) Lot number: 49



RE buffer #1: New England Biolabs (cat. B7001S) Lot number: 1007



RE buffer #2: New England Biolabs (cat. B7002S) Lot number: 03064



RE buffer #3: New England Biolabs (cat. B7003S) Lot number: 1107A



RE buffer #4: New England Biolabs (cat. B7004S) Lot number: 0030805



pGL4.26 vector (luc2/minP/Hygro): Promega (Madison, WI) (cat. E8441)



Shrimp Alkaline Phosphatase (SAP)



SAP buffer



T4 DNA ligase: New England Biolabs (cat. M0202L) Lot number: 1910801



T4 DNA ligase buffer: New England Biolabs (cat. B0203S) Lot number: 0303



SOC media: Invitrogen (cat. 460821) Lot number: 470041



LB broth



DH5α cells



XL2-Blue Ultracompetent cells: Stratagene (cat.200150) Lot number: 0006039741



Miniprep kit: GeneScript (cat. L00193) lot. MM00107
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Plasmid Maxiprep kit: Qiagen Qiafilter (10) (cat. 12262) Lot number:
ANL1012/BRL023/L02/133

3.1.7 Materials used for transfections


Opti-MEM Reduced Serum Media (cat.11058) Lot number: 544027



Lipofectin Transfection Reagent: Invitrogen (cat. 18324-020)



Luciferase substrate: Lucferin



β-gal substrate: chlorophenol red β-D-galactopyranoside (CPRG) Oz Biosciences
(cat: GC10002)



Dithiothreitol (DTT) obtained from Sigma Aldrich (D9779)



Microplate Analyser: Fusion™ Universal (PerkinElmer)



96 well plates: Corning (cat.3596)



96 well luminometer plates: Optiplate



Expression vectors:
o pCMV-βGal
o pRST7ERα
o pRST7ERβ



Reporter constructs:
o 3xERE-TATA-luc
o TGM2-luc



Software programs
o Microsoft Excel
o CLC Main Workbench 5
o Geospiza Finch TV 1.4
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3.2 Methods
3.2.1 Mammalian Cell Culture
All cell lines were obtained from American Type Culture Collection (Manassa,
VA) and cultured in media from Invitrogen (Carlsbad, CA). HeLa cells were maintained
in MEM, MCF7 cells in DMEM/F12 and SKBR3 and BT483 cells in RPMI 1640, each
supplemented with 8% charcoal-stripped foetal bovine serum (FBS) (Hyclone
Laboratories, Logan, UT), 1mM sodium pyruvate, and 0.1mM non-essential amino
acids (Invitrogen). All cell lines were propagated in a 37˚C incubator with 5% CO2.

3.2.2 Hormone/inhibitor treatment assays
One ml of 2x105 cells/ml in phenol red free media was plated in each well in 12
well plates. All ligand stocks were dissolved in ethanol or DMSO before use in cell
culture. After 2-day incubation cells were treated with a 10x concentration of hormone
or inhibitor diluted in spent media. 100µl of the 10x concentration of the appropriate
hormone/inhibitor treatment were added to each well and incubated for 8 hours (unless
otherwise stated). E2 was used in 10ng/ml concentration while all pharmacological
agents were used in concentrations ranging from 10nM to 1µM. After incubation cells
were washed in PBS and lysed with RNA lysis solution (Bio-Rad).

3.2.3 RNA isolation, cDNA preparation and quantitative PCR
Total RNA was isolated from cells using Bio-Rad Aurum Total RNA Mini Kit
according to the manufacturer‟s instructions, which included a DNase step. One µg of
RNA was reverse transcribed into cDNA using the Bio-Rad iScript cDNA synthesis kit
according to the manufacturer‟s instructions. In all cases, a cDNA reaction lacking
reverse transcriptase was performed to monitor possible genomic DNA contamination.
The Bio-Rad iCycler Real-time PCR System was used to amplify and quantitate the
levels of target gene cDNA. Quantitative PCR (qPCR) reactions were performed using
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8µl of diluted cDNA (1:15), 10uM specific primers and Qiagen SYBR green supermix
in a total volume of 13ul. The following cycling protocol was used for all reactions: 1
cycle at 95°C for 5 min, followed by 40 cycles consisting of 95°C for 15 sec, 60°C for
30 sec and 72°C for 30 sec. A final cycle at 72°C for 7 min followed. A melt curve
analysis from 70-90°C (0.5°C/10 sec increments) was performed for all reactions to
detect primer dimers or other transcripts. A single PCR product was detected in all
cases. Each cDNA reflecting each biological sample were run in triplicate and
expressed as an average +/- SEM.

3.2.4 Plasmids
3.2.4.1 Expression plasmids
The pRST7-ERα plasmid is a CMV - driven expression plasmid containing
amino acids 1-595 of the full length human ER [19]. The pRST7-ERβ plasmid is a
CMV driven expression plasmid containing amino acids 1-477 of the full length human
ERβ [83]. pCMV-β-Gal (obtained from Clontech, Palo Alto, CA) is a mammalian
vector expressing a β-galactosidase gene driven by the human cytomegalovirus
immediate early gene promoter.
3.2.4.2 Reporter constructs
The pTGM2-luc plasmid (Figure 3.2) was constructed as follows: an empty
pGL4.26 plasmid (Figure 3.1) (obtained from Promega) was digested with XhoI and
ligated to a 1.7kb fragment (previously digested with XhoI) spanning the TGM2
regulatory element isolated from gDNA. The sequences of the oligonucleotides were:
forward

5‟-GGAACTCGAGCTGTGAGGGAGGGATTCTTT-3‟

and

reverse

5-

GGAACTCGAGCGGACAGGGACACACAACTA-3‟. The following PCR protocol
was used: 1 cycle at 95°C for 2 min, followed by 32 cycles consisting of 95°C for 30
sec, 62°C for 40 sec and 72°C for 2 min. A final cycle at 72°C for 5 min followed. The
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ligated plasmid was transformed into XL2-Blue ultracompetent cells and grown at 37°C
overnight on Ampicillin plates. Colonies were re-cultured in 10mls of LB broth + 200µl
Ampicillin (1mg/ml) at 37°C overnight. Plasmid isolation was performed on 1ml of
transformed XL2 cells according to the manufacturer‟s instructions. Isolated plasmids
were XhoI digested to identify clones with the insert. The correct orientation was
confirmed by analysis of the restriction fragment length using HindIII and BglII. A
large plasmid isolation was used to isolate 1ml of purified pTGM2-pGL4.26 plasmid.
3xERE-TATA-luc is a luciferase reporter vector containing three tandem repeats
of the consensus ERE upstream of the human TATA promoter sequence inserted into
the multiple cloning site of pGL3-basic vector.
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Figure 3.1 pGL4.26 vector, obtained from Promega

Map of pGL4.26 plasmid obtained from Promega, showing β-lactamase gene
(Ampicillin resistance), luciferase reporter gene (luc2), multiple cloning region
containing XhoI restriction site, minimal promoter (TATA box) and mammalian
selectable marker (hygromycin).
Figure 3.2 TGM2-luc plasmid
TGM2 insert
XhoI

β-lactamase (Amp R)

XhoI
Minimal Promoter
Luc2 reporter gene

Map of cloned TGM2-luc plasmid with Ampicillin resistance gene (β-lactamase),
luciferase reporter gene (luc2) and the TGM2 insert (5‟ flanking region)
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3.2.5 Mammalian Cell Culture and Transfections
All cells were plated in phenol red free media in 24-well plates 24h prior to
transfection. Cells were transfected in OptiMEM I Reduced Serum Medium
(Invitrogen) with 3μg of total plasmid per triplicate sample in 24-well, using
Lipofectin® according to manufacturer‟s protocol (Invitrogen). 100ng of the pCMVßGal normalization vector was used with 0, 10 or 20ng of ERα expression vector and
luciferase reporter constructs making up the remaining. DNA-Lipofectin mix was added
and incubated for 4 h. All ligand stocks were dissolved in ethanol or DMSO before use
in cell culture, and cells were treated with ligands added to phenol-red-free media. A
saturating concentration of ligand was added to the cells 20-24 hr prior to assays: 10nM
E2, 1µM 4OHT, 1µM ICI, 100ng/µl IL-6 or 1µM ATRA (All Trans Retinoic Acid).
Cells were lysed 24-28hrs after transfection and assayed for luciferase and galactosidase activities using a Fusion™ Universal Microplate Analyzer (PerkinElmer).
Results are expressed as normalized luciferase activity (NLA, normalized with gal for
transfection efficiency)  SD per triplicate sample of cells. Statistic analysis was
performed on these results using the t-test to compare the difference between two
groups of data.
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4 Results
4.1 Background
4.1.1 Oestrogen Receptor Signaling in the Breast
Oestrogens function as mitogens in most ER-positive breast cancers. Upon
ligand binding, ER undergoes a conformational change that results in dimerisation,
DNA binding, recruitment of transcriptional coregulators, and modulation of target gene
expression. The implication of oestrogens and ER in breast cancer has led to the
pharmaceutical development of SERMs and anti-oestrogens. SERMs exhibit tissueand promoter-specific agonist and antagonist behaviour. The unique and compoundspecific conformational change in ER induced by SERM binding allows different
protein-protein interaction surfaces to be exposed, leading to differential recruitment of
co-regulatory proteins and thus diverse biological outcomes. The ER regulates a large
set of genes in the breast cancer cell. Genes activated by the ER are generally involved
in proliferation and cell survival while genes inhibited by ER are generally involved in
halting the cell cycle. Therefore SERMs prevent the growth of breast cancer cells by
inhibiting ER-regulated genes.
It is not fully known however how a patient on TAM develops a de novo or an
acquired resistance to the drug. Therefore understanding the biology of ER/TAM
control of gene expression is critical to understanding how resistance to TAM may
develop. As described in the introduction, TG2 expression has been shown to be upregulated in drug-resistant and metastatic breast cancer cells and is thought to contribute
to TAM resistance [84].
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4.2 ER control of TGM2 expression
It has been previously shown that E2 activates the TGM2 gene. As discussed
earlier TGM2 is involved in many processes within the cell. As TGM2 is an ERregulated gene, we would expect this gene to be inhibited by TAM.
In this study, we focused on defining the molecular mechanisms underlying
TAM inhibition of TGM2 in the context of breast cancer cells.
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4.2.1 Time-course of ligand treatments on TGM2 expression
Our first objective was to evaluate the activation of TGM2 by E2 in MCF-7 cells
over a 6 hr time-course. The concentrations of each ligand required were examined in
the next experiment; however for this experiment we used physiologically relevant
ligand concentrations. [85] Also cells were treated with 4OHT and β-Napthoflavone
(BNF) over a six hour time-course as these were used in later experiments. BNF is an
Aryl Hydrocarbon receptor agonist and is used is this study to investigate the effects of
TAM on AhR-controlled genes. This experiment aims to identify the length of
incubation required for optimum gene activation and mRNA production. pS2 (trefoil
factor 1), an ER-regulated gene highly expressed in breast cancer cells, was used here as
a positive control. Figure 4.1 shows the plate setup for this experiment.

Figure 4.1 Plate setup for MCF-7 cell culture
1hr

2hr

4hr

6hr

6hr

10nM E2

Control

100nM 4OHT

E2 +
4OHT
E2 +
BNF

100nM BNF

1ml of 2x10^5 MCF-7 cells/ml were plated in 15 wells of two 12 well plates. Cells were
diluted in phenol red free DMEM//F12 media (+8% CFS with NEAA and Na Pyruvate)
Cells were incubated for 48hrs to achieve confluency. Dilutions of ligands were made
up in spent media and added to the appropriate wells to make to make a final volume of
1ml/well.
After the incubation period, RNA was isolated from each cell culture well and
quantified. Table 7.1 UV quantification of isolated RNA (Raw data) shows the UV
quantification values for each of the RNA samples. The volume of isolated RNA
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required to give 1µg/well in the iScript Reverse Transcriptase reaction was calculated
by dividing 1µg by the concentration of RNA (µg/ml).
Each well in the Reverse Transcriptase (RT) reaction contained 1µl Reverse
Transcriptase enzyme (iScript), 1µg of RNA and made up to a final volume of 16µl
with RNase-free water (Table 7.2). A no-RT (NRT) control also was set up as a
negative control which contained RNA but no RT enzyme. The RT samples were run on
a single PCR cycle according to manufacturer‟s instructions.
The cDNA produced in the RT reaction was subjected to real-time PCR
(qPCR) for quantification. In addition to the 15 samples and NRT, a set of standards
were set up. This was done by pooling 1µl from each cDNA sample (15µl) and diluting
the cDNA in a set of serial dilutions to give 1x, 0.2x, 0.1x and 0.02x concentrations.
Each sample was run in triplicate for each of the primers analysed. An example of the
qPCR results are presented in Figure 4.2, which shows the data for 36B4 and TGM2
analysis. 36B4 is a house-keeping gene which is transcribed at a constant rate,
regardless of cell treatments. It is analysed as an internal standard for the purpose of
normalising qPCR data.
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Figure 4.2 PCR quantification curve for 36B4 and TGM2 primers

TGM2

36B4

PCR cycle number (X-axis) and fluorescence (Y-axis). The graph shows the increasing
uptake of Sybr green (fluorescent dye) as it binds amplified dsDNA in each well. Sybr
green fluoresces intensely while intercalated in the minor groove of double stranded
DNA. The cycle at which the amount of fluorescence exceeds a threshold value (orange
line) is known as the CT (Threshold cycle). The CT relates to the concentration of cDNA
present at the start of the run. The first set of curves to cross the threshold line
represents analysis of 36B4, followed by curves for TGM2 analysis. The earlier the
curve crosses the threshold, the higher the amount of cDNA present at the start of the
run.

The first set of data on the graph to cross the threshold value is 36B4, followed by
TGM2. This means that 36B4 is in higher concentration than TGM2. The CT values for
each sample are exported to a spreadsheet for analysis. For each primer used in the
qPCR experiments a melt curve (Figure 4.3) and a standard curve (Figure 4.4) is
performed. Upon completion of the PCR reaction a melt curve was performed to test for
the presence of primer dimers or contaminating primers. The presence of a single peak
on the melt curve for each primer confirms the presence of a single PCR product. The
results of this analysis are presented in Figure 4.3.

47

Figure 4.3 Melt curve for 36B4 and TGM2 primers

The melt curve shows the temperature dependent dissociation between two DNA
strands, in this case the amplified product. The dissociation of the DNA during heating
is measureable by the large reduction in fluorescence that results. The graph shows the
change in fluorescence (y-axis) vs. temperature (x-axis) for 36B4 and TGM2 amplified
products. The melt curve is useful for determining the specificity of the primers used as
primers may induce primer-dimer formation or amplify other non-specific products. The
presence of a single peak for each primer indicates that no primer dimer or other nonspecific products have been produced.
The results of the melt curve indicate that the PCR reaction has no
contamination and that single product was formed. A standard curve is also performed
for each qPCR reaction in this study which is used to examine PCR efficiency. The
standard curve is presented in Figure 4.4. The graph shows there is a direct correlation
(r = 0.998) between the relative log concentrations of the samples/standards and the
threshold cycle. The unknown sample (in red) is the NRT which has practically no
detectable cDNA.
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Figure 4.4 qPCR Standard curve for 36B4

The relative starting concentrations of cDNA (x-axis) are graphed against the threshold
cycle (y-axis) for each of the standards. The graph shows the standards (in blue)
analysed in this experiment. The NRT samples were run as a negative control (in red).
The slope of the curve is directly related to the efficiency of the PCR reaction. At a PCR
efficiency of 100% the template DNA doubles after each cycle during exponential
amplification.
The relative gene expression for each sample was calculated according to the 2^ ΔΔCT method using Microsoft Excel [86]. This method normalises the CT from each
sample to its untreated control, which is then normalised again to its respective 36B4 CT
value to give a ΔΔCT value. 36B4 is used in this study to normalise all other genes as its
expression remains unchanged regardless of cell treatments. The fold change in gene
induction is given by the formula 2^-ΔΔCT.
The results for the assay described in Figure 4.1 are presented in Figure 4.5. In
this experiment the cells were treated with no ligand (control), E2, 4OHT, BNF, or
combinations of the ligands prior to RNA isolation, RT-PCR and qPCR for 36B4,
TGM2 and pS2.
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Figure 4.5 Time-course of gene expression in MCF-7 cells
Normalised Fold Change
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E2 + E2 +
4OHT BNF
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pS2

B

1hr

1.5

1.0

0.5

0.0
control

1hr

2hr

4hr

10nM E2

6hr

1hr

2hr

4hr

100nM 40HT

6hr

1hr

2hr

4hr

100nM BNF

6hr

6hr

6hr

E2 + E2 +
4OHT BNF

MCF-7 cells (2x10^5 /well) were treated with vehicle (control), 10nM E2, 100nM
4OHT, 100nM BNF for 1, 2, 4 or 6hr intervals. Cells were harvested and cDNA
prepared from isolated RNA was subjected to qPCR analysis. qPCR was performed to
analyze TGM2, pS2 and 36B4 gene expression. Data are normalized to the 36B4 gene
and expressed as mean fold change over vehicle ± SEM for triplicate amplification
reactions. All qPCR data in this study was calculated using the 2-ΔΔCT method to
produce a normalised fold change [86]. Asterisks: unpaired two-tailed T-test, * p value
> 0.05 (no significant difference), ** p value < 0.01.
The qPCR results show that incubating the cells with ligand for 6 hrs after
ligand treatment is sufficient for TGM2 (A) and pS2 (B) mRNA up-regulation. BNF or
4OHT do not activate transcription of these genes. Treatment of E2 in combination with
4OHT inhibits E2 induced pS2 mRNA expression but not TGM2. Statistical analysis
using the Students t-test shows no significant difference (p<0.01) between TGM2
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mRNA expression in either E2-treated or E2/4OHT co-treated cells. This finding
suggests that 4OHT is unable to inhibit E2-induced TGM2 mRNA expression. The next
objective was to identify the concentration of ligands that are required for optimum
gene transactivation.

4.2.2 To determine optimum ligand concentrations for TGM2 mRNA
expression
Determining the required concentration of ligands for activation of gene
transcription is also required for future pharmacological experiments. RET (RET protooncogene) is used here as a positive control (ER-regulated gene). All qPCR experiments
were performed as outlined in experiment 4.2.1.

Normalised Fold Change

Figure 4.6 Dose-response curve of TGM2 induction.
20.0
15.0

TGM2
A

10.0
5.0
0.0
-

10nM

Normalised Fold Change

control

7.0
6.0
5.0
4.0
3.0
2.0
1.0
0.0

B

control

100nM

1uM

0.1nM

4OHT

1.0nM

10nM

100nM

10nM

100nM

E2

RET

10nM

100nM

1uM

0.1nM

4OHT

1.0nM
E2

MCF-7 cells were treated with increasing concentrations of E2( 0.1 - 100nM),
4OHT (10 - 1000nM). Cells were harvested and cDNA prepared from isolated
RNA was subjected to qPCR analysis. Data are normalized to 36B4 and
expressed as mean fold change over vehicle ± SEM for triplicate amplification
reactions.

51

The qPCR results for TGM2 show a high standard error which may suggest a
problem with the PCR protocol or polymerase enzyme stability. The DNA polymerase
enzyme may have been allowed to reach room temperature prior to the start of the
qPCR run, resulting in imprecise data. The results do show however that between 1100nM E2 is sufficient for activation of RET and TGM2. A concentration of 10nM E2
and 1µM 4OHT and an incubation time of 6 hours was chosen for future experiments.

4.2.3 TAM fails to inhibit ER-activation of TGM2
Results presented in Figure 4.5 indicate that 4OHT fails to inhibit E2-induced
up-regulation of TGM2; this experiment was repeated using 4OHT and a SERD, ICI as
a pharmacological control. RET is used as a control E2-regulated gene. ICI works
through a different mechanism than TAM, by inducing rapid degradation of ER.

Figure 4.7 E2-induced activation of TGM2 is not inhibited by TAM
*

7.0
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6.0
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0.0
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8.0
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3.5
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0.5
0.0

E2 &
ICI
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E2 4OHT E2 &
ICI
(10nM) (1uM) 4OHT (1uM)

E2 &
ICI

MCF-7 cells were treated with vehicle (control), 10nM E2 with either 1µM 4OHT or
1µM ICI for 6hr. Cells were harvested and cDNA prepared from isolated RNA was
subjected to qPCR analysis. Data are normalized to 36B4 and expressed as mean fold
change over vehicle ± SEM for triplicate amplification reactions from one
representative experiment. Asterisks: unpaired two-tailed Student‟s T-test, * p value >
0.05 (no significant difference), ** p value < 0.01.

52

The results show that both RET and TGM2 are both induced by E2. However
4OHT treatment in combination with E2 resulted in a significant decrease in RET
expression, while no significant decrease in TGM2 expression was observed. Statistical
analysis using the Student‟s t-test shows that there is a significant difference (p <0.01)
in RET gene expression between E2 and E2/4OHT treated cells whereas there is no
difference (p >0.05) in TGM2 expression between E2 and E2/4OHT treated cells. This
suggests that TAM is unable to inhibit E2-mediated activation of TGM2. ICI however is
able to fully inhibit E2-induced activation of both TGM2 and RET.
SERDs work by inducing rapid re-compartmentalisation and degradation of ERα
protein while SERMs block ligand induced activation of the ER. This indicates that
TAM is binding the ER and preventing transcription of RET but not TGM2. ICI is able
to inhibit TGM2 transcription since it leads to degradation of the ER. This left us with
the task of investigating why TGM2 is not inhibited by TAM when other ER-regulated
genes are, and what is the possible biological significance of this.
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4.2.4 Is ER required for TGM2 up-regulation?
In the following set of experiments we examined the role of some of the cellular
factors required for the up-regulation of TGM2. We have already shown that E2 is
required for activation of this gene (Figure 4.5). This experiment investigates the role of
ERα in TGM2 activation.
Transfection of an ERα plasmid into MDA-231 cells is used to identify the role
of ERα in TGM2 induction. MDA-231 (ER negative) breast cancer cells were
transfected with the ERα expression vector. Cells are treated with E2 and with 4OHT in
combination with E2. qPCR was performed using primers for WISP2 (WNT1 inducible
signaling pathway protein 2), an ER responsive gene, 36B4, and TGM2. βgal is used as
a negative control as it does not have a canonical ER binding site and is not activated by
oestrogen signalling.
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Normalised Fold Change

Figure 4.8 ERα transfection of MDA-231 cells
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MDA-231 cells treated with either ERα expression vector or βGal (negative control)
and treated with 10nM E2 in combination with either control (V) or 1µM 4OHT. Cells
were harvested and cDNA prepared from isolated RNA was subjected to qPCR
analysis. Data are normalized to the 36B4 gene and expressed as mean fold change over
vehicle ± SEM for triplicate amplification reactions. Asterisks: unpaired two-tailed Ttest, * p value < 0.01.
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WISP2 qPCR data show good E2-induced activation of transfected ERα
confirming that ER activates WISP2 and ER transfection was successful. Statistical
analysis using the Student‟s t-test shows there is a significant difference (p <0.01)
between TGM2 induction in cells treated with E2 which have the ERα over cells treated
with βgal. The results however do show poor activation of TGM2 which may be due to
inadequate RT/qPCR efficiency or insufficient ERα transfection. These results further
confirm that TGM2 is an E2-regulated gene. The addition of 4OHT to cells treated with
E2 and transfected with the ERα plasmid induces an inhibition of WISP2 while having
no effect on TGM2 mRNA expression. These results also confirm data from previous
experiments where TAM is unable to inhibit E2-induced up-regulation of TGM2.
To understand why this gene is not inhibited by TAM we must examine the
involvement of other cofactors which may be preventing this inhibition. The following
experiment examines the possible role of the Aryl Hydrocarbon Receptor (AhR) in
preventing TAM inhibition of TGM2. We hypothesized that activated AhR prevents ER
inhibition of the TGM2 gene by a process which is distinct from other ER regulated
genes. The following experiment investigates the role of TAM on the AhR and the
effects of activated AhR on transcription of the TGM2 gene. The aim of this is to
investigate if TAM activation of AhR is responsible for the continued up-regulation of
TGM2 in the presence of E2 and TAM through the process of AhR-ER cross-talk.
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4.2.5 Tamoxifen activates the Aryl Hydrocarbon receptor (AhR)
It has been previously shown that TAM can activate CYP1A1, an AhR (ArylHydrocarbon Receptor) regulated gene independently of the ER [87]. MCF-7 cells are
treated with E2, 4OHT and BNF over a 6 hour time-course. BNF (β-Napthoflavone), an
AhR agonist, is used here as a positive control.

Normalised Fold Change

Figure 4.9 Dose-response curve of TGM2 induction.
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MCF-7 cells (2x10^5 /well) were treated with vehicle (control), 10 nM E2, 100nM
4OHT, 100nM βNF for 1,2,4 or 6hr intervals. Cells were harvested and cDNA prepared
from isolated RNA was subjected to qPCR analysis. Data are normalized to the 36B4
gene and expressed as mean fold change over vehicle ± SEM for triplicate amplification
reactions.
Results presented in Figure 4.9 show that 4OHT and βNF (positive control) will
activate the CYP1A1 gene (at an optimum incubation of 4 hr) confirming that 4OHT
does activate AhR as an off-target effect. This is where a drug binds to and activates a
receptor which is not its intended target.
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In previous experiments we have shown that ER is required for TGM2 gene
expression. However because TAM activates AhR, we must also investigate if AhR is
capable of maintaining TGM2 gene expression in the presence of TAM. To do this we
treated MCF-7 cells with ligands which activate the AhR and measured subsequent
TGM2 mRNA expression.
Figure 4.10 shows the effects of the AhR-activating ligands, TAM and BNF on
TGM2 mRNA expression. These results show that treatment of MCF-7 cells with AhR
ligands alone is not sufficient maintain to mRNA expression of TGM2. The data from
this experiment show that activated AhR alone is unable to activate this gene.

Figure 4.10 Effects of AhR ligands on TGM2 activation.
Normalised Fold Change
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MCF-7 cells (2x10^5 /well) were treated with vehicle (control), 10 nM E2, 100nM
4OHT, 100nM βNF for a 6hr incubation. Cells were harvested and cDNA prepared
from isolated RNA was subjected to qPCR analysis. Data are normalized to the 36B4
gene and expressed as mean fold change over vehicle ± SEM for triplicate amplification
reactions.
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4.2.6 Array of SERMs on TGM2 activation
Although we have shown that TAM cannot inhibit E2 induced TGM2 mRNA
expression, we sought to determine whether structurally related breast cancer drugs
show similar results. In this experiment we analysed the effects of an array of SERMs
and SERDs on E2-mediated activation of TGM2.
Figure 4.11 Effect of SERMs on TGM2 activation
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MCF-7 cells were treated with vehicle (control) or 10 nM E2 and either 1µM ICI,
4OHT, Tamoxifen, Endoxifen, Raloxifene, Lasofoxifene or Bazedoxifene and incubated
for 8hr. Cells were harvested and cDNA prepared from isolated RNA was subjected to
qPCR analysis. Data are normalized to 36B4 and expressed as mean fold change over
vehicle ± SEM for triplicate amplification reactions.
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These data are the first indication that Endoxifen (Endox) is also unable to
inhibit TGM2. As stated earlier Endoxifen, a secondary metabolite of 4OHT is as potent
as 4OHT with respect to ER binding and inhibition of E2 induced cell proliferation.
However in this experiment we did not achieve full inhibition of the control gene RET;
this may be due the poor solubility of some of these drugs in media. Also Tamoxifen is
known to undergo spontaneous rearrangement from its trans to cis forms resulting in a
weak anti-oestrogen. A dramatic solvent effect has been observed on the rate of the
process of molecular rearrangement [88]. This may explain the lowered efficacy of
Tamoxifen in these set of results. To help overcome these solubility issues we used
serial dilutions when diluting ligands, while all ligands were kept on ice.
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4.3 Cloning TGM2 response elements
At this point we have displayed the differential pharmacology of TAM on ER
activation of TGM2 in the context of breast cancer cells. The cell culture assays have
shown us that TAM is unable to inhibit E2/ER-induced activation of TGM2 while other
agents such as ICI fully inhibit this activation. The next step in this study is to
investigate the genetic requirements for E2 activation of TGM2. This involves cloning a
short segment of the promoter region into a Luciferase plasmid for use in cell
transfection assays. By designing primers to different response elements on the TGM2
promoter we can clone these regions and investigate the precise sequence requirements
of the ER/E2/TAM activation complex.
The first step is to perform a bioinformatics study on the TGM2 DNA sequence.
The

entire

genomic

sequence

for

chromosome

20

was

downloaded

(www.bioinfo.ut.ee/HMgenome/CEU) and the exons/introns located along with the
putative ERE.
Figure 4.12 Layout of exons on TGM2
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Exons within the TGM2 gene are labelled 1 to 13, drawn to scale.

The putative ERE and AP-1 sites were found by performing a nucleotide
sequence search using Bio-informatics software (CLC Main Workbench 5.0)
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Figure 4.13 Putative ER binding regions in the TGM2 promoter

A further literature search highlighted two other possible ER binding regions on
the TGM2 gene based on a genome-wide study of ER binding sites (Figure 4.14). [35]
These regions which were identified by chip-on-chip analysis located the binding sites
to within 600bps. One is located 3kb upstream of the transcription start site (Figure
4.16), while the other is located within exon 9 (Figure 4.17). There are also three SP-1
sites located just upstream of the gene promoter which may also indirectly drive ERmediated transcription.
Figure 4.14 Location of ER binding sites
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Data concerning the locations of these ER binding sites was downloaded from the
supplemental data supplied with the published data on the Harvard University website
(http://research.dfci.harvard.edu/brownlab/datasets/index.php?) [35]
The next step was to design a series of primers to cover the TGM2 regulatory
region and the two putative ER binding sites shown above. All primers were produced
with an Xho1 cutting site on the 5‟ end for ligating the PCR products into the Luciferase
vector. The list of primers is outlined in the Materials and Methods section (Table 3.3).
These were named by their relative position to the transcription start site (Figure 4.15).
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Different combinations of these forward and reverse primers can be used to amplify the
required sequences.
Figure 4.15 Location of primers on TGM2 5’ flanking region
ERE-1120
F-1665

F-900

F-690

pERE

F-561

Start site

R-540 R-480

R-305

ERE+440

R+50

Primers were designed to a length of 20bps with a GC content of 45-55% and an
annealing temperature of 55-60°C. All primers have an Xho1 binding site attached.

Figure 4.16 Location of primers on upstream putative ER binding site

F-UBS F-560

Putative ER binding
site

-4kb

-3.5kb

-3kb

-2.5kb
R-UBS

R+550

Figure 4.17 Location of primers on Exon 9/ER binding site

Primers were designed spanning the putative ER binding region and exon 9. An extra
set of primers located on either side of the exon gave the option of isolating the region
upstream or downstream of the exon. Primers are named relative to their position to the
putative ER binding site.
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4.4 PCR of genomic DNA
Having designed the primers, PCR reactions were set up in order to amplify the
particular DNA elements. Genomic DNA was isolated from MCF-7 cells. PCR was first
performed with the primers targeting the full length (1.7kb) TGM2 regulatory region as
in Figure 4.15. The PCR protocols used are described in the Materials and Methods.
PCR amplification of the full length TGM2 regulatory region was first performed using
the primers “Forward-1645” and “Reverse +50” in a temperate gradient PCR cycle
(Figure 4.15). Repeating this protocol with the addition of varying amounts of DMSO
(Dimethyl Sulfoxide) (1-7%) and the use of either Pfu Turbo enzyme or GC Advantage
2 polymerase did not result in any visible bands (Figure 4.18). In the process of
optimising PCR conditions, PCR was repeated for all combinations of forward and
reverse primers surrounding the putative ERE (Figure 4.15) and run on agarose gel,
however no visible specific bands were produced.

Figure 4.18 PCR amplification of full length TGM2 regulatory region
ML

48°

Temp.

60°

ML

Agarose gel of PCR amplified gDNA using the temperature gradient 48-60°C. ML, 1kb
DNA molecular weight ladder.

64

After redesigning primers for this region (“ERE-1120” and “ERE+440”) (Figure
4.15), this protocol was repeated with the new set of primers with increasing
concentrations of DMSO (0, 3 and 5%) and at temperature gradients of 56-66°C.

Figure 4.19 PCR amplification of full length TGM2 regulatory region
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0% DMSO (A) shows unspecific bands, PCR preformed at gradient temperature (5666°C). Addition of 3% or 5% DMSO (B) and (C) gives a specific band at 1.7Kbps. This
sequence is be referred to as pTGM2 (TGM2 promoter) in the following experiments.
The specific bands were cut from the gel and the DNA isolated. This sequence
contains the 5‟ TGM2 regulatory region containing the putative ERE and AP-1 sites as
shown in Figure 4.13. With the isolated DNA as a template (pTGM2), we used a
separate set of primers (“Forward 561” to “Reverse 305”) which target a short sequence
within the template sequence in a PCR reaction (Figure 4.15). This was done to confirm
that the correct sequence was amplified from genomic DNA.
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Figure 4.20 PCR amplification of a 250bp sequence using pTGM2 as a template
1

2

3

ML

250bp

The amplified sequence from primers “ERE-1120” and “ERE+440” (pTGM2) was used
as a DNA template in this reaction. Primers used were “Forward 561” to “Reverse 305”.
The presence of PCR products (shown in triplicate) proves that the correct 1.7kb
sequence was amplified (Figure 4.19)
PCR was performed using the primers “Forward-690 and Reverse-480” and the
pTGM2 sequence as a template (Figure 4.15). The target sequence contains the putative
ERE, located about 650bps upstream of the transcription start site (Figure 4.13). PCR
was performed at a temperature gradient of 52-60°C.
Figure 4.21 PCR amplification of putative ERE at position -650bp
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PCR products were run on 1% Agarose gel with a 100bp molecular ladder. Product size
is 220bps including the XhoI binding sites attached to either end. This sequence
contains the putative ERE as described earlier.
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In order to amplify the downstream putative ER binding site (Figure 4.17), PCR
was performed on gDNA using primers targeting a 1.9kb sequence on exon 9 using the
primers “Forward-1200” and “Reverse+700”. A temperature gradient from 46-58°C
was set up on the PCR thermocycler in order to find the optimum primer annealing
temperature (Figure 4.22).
Figure 4.22 PCR amplification of 1.9kb of TGM2 exon 9
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PCR reaction was performed at a temperature gradient of 46-58°C. Products were run
on 0.75% Agarose gel (+Ethidium Bromide) with 1kb molecular ladder.
The PCR products from the most specific bands (at 46-50°C) were isolated and
Xho1 digested for ligating into the Luciferase vector in later experiments. To isolate the
upstream putative ER binding site (Figure 4.16), PCR was performed using the primers
“Forward UBS” and “Reverse UBS” at a gradient of 48-56°C.
Figure 4.23 PCR amplification of upstream putative ER binding site
ML

48°

Temp.

56°
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PCR of the upstream putative ER binding region using the primers “Forward UBS” and
“Reverse UBS” did not result in any specific DNA product.
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Primers to this region (Figure 4.16) were redesigned (F-560 and R+550) and the
PCR was repeated using different combinations of forward and reverse primers (Figure
4.24). PCR reactions B and C produced a visible DNA product. Since the expected size
of the product is 1.7kb, the DNA sequence in reaction B is more than likely not the
correct target sequence.
Figure 4.24 PCR amplification of upstream putative ER binding region
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Four sets of PCR reactions (A-D) were set up using the primers: (A) Forward UBS-560
and Reverse UBS+550 (B) Forward-UBS and Reverse UBS+550 (C) Forward UBS-560
and Reverse-UBS (D) Forward-UBS and Reverse-UBS. The PCR reaction was run at a
constant temperature of 52°C and PCR products were run on 1% agarose gel. The same
reaction was set up with 1% DMSO, this achieved the same results as shown above.
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As the primers in reaction (C) gave a specific DNA product of the expected size
(1.7kb), these were used in subsequent experiments. A PCR reaction was set up using
the primers “Forward UBS-560” and “Reverse-UBS” and run at a gradient of 50-60°C
using gDNA as a template.
Figure 4.25 UV visualization of agarose gel
50°

60°

Temp.
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1.7 kb

The PCR products were run on a 1% agarose gel with a 1kb molecular ladder. The DNA
from the specific bands was cut from the gel and isolated using a DNA gel isolation kit.
The isolated DNA which is referred to as UBS (upstream binding sequence) was Xho1
digested for use in future ligation experiments.
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4.5 Ligations
The pGL4-26 vector (Promega) was used in all ligation experiments, this
contains a minimal promoter, an Ampicillin resistance gene (β-lactamase) and a luc2
(Luciferase) reporter gene. (Figure 4.26)
Figure 4.26 Promega pGL4.26 plasmid with minimal promoter

Sizes and locations of the specific plasmid components were obtained from the pGL4
luciferase manual. The map was constructed using Bio-informatics software.
The pGL4.26 plasmid and the full length (1.7kb) TGM2 regulatory sequence
insert (Figure 4.19) were digested overnight with Xho1 restriction enzyme. pGL4.26
was treated with Shrimp Alkaline Phosphatase (SAP) to remove 5‟ phosphates,
preventing re-ligation of the plasmid. Both DNA strands were run on a 1% agarose gel
to determine volumes required for ligation reaction. (Figure 4.27).
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Figure 4.27 Xho1 digested pTGM2 and pGL4.26
ML

1

2

ML

5.8 kb

1.7 kb
pTGM2

pGL4.26

Digested pTGM2 and pGL4.26 were run on a 1% agarose gel with a 1kb molecular
ladder. The intensity of the bands indicate their relative concentrations, which is used to
determine the volumes required for the ligation reaction

Multiple ligation reactions were set up with T4 DNA ligase (1.5µl), 10x ligase
buffer (1.5µl), the insert (6µl) and varying volumes of plasmid (0.5µl to 2.0µl) to a final
volume of 15µl. Also a vector-only ligation was set up as a negative control. The
ligation mixtures were incubated at room temp for 1-2hrs prior to transforming in XL2
ultra-competent

cells

(Stratagene)

according

to

manufacturer‟s

instructions.

Transformed cells were plated on Ampicillin plates and incubated at 37°C overnight.
All colonies (3) were re-cultured in 10mls of LB broth with added Ampicillin, while the
vector-only control did not grow any colonies. Plasmid isolation was performed on the
4 cultured broths to isolate the ligated plasmid. Each plasmid isolate was quantified,
Xho1 digested, and run on 0.75% agarose gel.
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Figure 4.28 UV visualisation of three isolated plasmids
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1µg of each isolated plasmid was run on 0.75% agarose gel. Sample number 3 has both
the vector (5.8kb) and the insert (1.7kb) while both 1 and 2 have the plasmid only.
The plasmid from sample number 3 was shown to contain the insert (referred to
as pTGM2-luc in future experiments). The next step is to determine whether or not the
insert is in the correct orientation. Two restriction enzyme digests were set up using
HindIII and BglII as each of these enzymes cut both the insert and the vector in one
position only. By analysing the size of the fragments, the orientation of the insert can be
determined. Plasmid isolation using a Maxiprep kit was performed to isolate a large
volume of the plasmid (pTGM2-luc). The isolated plasmid was quantified for use in
transfection studies.
Figure 4.29 Locations of HindIII and BglII cutting sites on TGM2-luc

BglII -200bp- BglII

HindIII

-1400 bp-

HindIII

The diagram shows the pTGM2 insert, the multiple cloning site and the luciferase gene.
As the distance between the two HindIII sites is 1.4kb and the total plasmid size is
7.4kb, a HindIII digest will produce fragment sizes of 1.4 kb and 6 kb. Also a BglII
digest will produce fragment sizes of 7.2 kb and 200 bp. These exact fragment sizes are
only formed when the pTGM2 sequence is inserted in the correct orientation.
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Figure 4.30 HindIII and BglII restriction digest of isolated pTGM2-luc
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The isolated plasmid (pTGM2-luc) was digested with HindIII (Lane 1) and BglII (Lane
2) in a single digest reaction. The fragments sizes from the HindIII digest were 6kb and
1.4kb while the fragment sizes from the BglII digest were 7.2kb and 200bp. Therefore
we can conclude the insert is in the correct orientation.

The pTGM2-luc plasmid was then sequenced to confirm that the correct
sequence from the TGM2 promoter region is incorporated into the plasmid (Figure
4.31).
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Figure 4.31 Chromatogram of sequenced pTGM2-luc plasmid

This figure shows part of the chromatogram of sequenced pTGM2-luc viewed using
Geospiza Finch TV 1.4. Highlighted in blue is the primer sequence used to amplify the
TGM2 insert, indicating the start of the inserted sequence. Not shown is the putative
ERE which is downstream of the sequenced region.

The sequence data was aligned with the TGM2 sequence using the Bioinformatics software CLC Main Workbench 5.0. Figure 4.32 shows a perfect alignment
between the sequenced insert and the actual TGM2 target sequence.
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Figure 4.32 Alignment between sequenced insert and expected sequence

Figure shows comparison between sequenced insert (pTGM2-luc) and genomic
sequence. Alignments were analysed using Bio-informatics software.

We decided to focus on the cloned TGM2-luc plasmid and proceed with
transfection studies using this plasmid to ascertain the transcriptional regulation of
TGM2 by ER in presence and absence of E2/TAM.
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4.6 Transfections
At this point 1.7kb of the TGM2 promoter region has been cloned into a
Luciferase plasmid. In order to study the regulation of TGM2 by ER with E2 or TAM,
the pTGM2-luc plasmid (Figure 4.33) was transfected into HeLa cells.
Figure 4.33 pGL4.26 luciferase vector with 1.7kb TGM2 insert

TGM2 insert

β-lactamase (Amp R)
Sequenced region

Minimal Promoter
Luc2 reporter gene

Diagram of the constructed luciferase plasmid containing the luciferase gene, minimal
promoter and TGM2 promoter insert, indicating sequenced region.
Both ER positive and ER negative cancer cells were used in the transfection
studies. In order to investigate the requirements of ER in the activation of TGM2, a
transfection assay was set up using ER negative HeLa cells. In this assay a CMV-driven
ERα plasmid was co-transfected with either pTGM2-luc, ERE-luciferase (3xERETATA-luc) reporter (positive control) or the empty vector (pGL4.26) as a negative
control. All cells in the transfection experiments are co-transfected with 100ng CMV-βgal

(Figure

4.34).

The

β-galactosidase

substrate

Chlorophenol

red-β-D-

galactopyranoside (CPRG) was added to the cell lysates and incubated at 37°C. The
absorbance of each well was measured at 570nm, which was used to normalise the
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luciferase activity for transfection efficiency. The results of this transfection are
presented in Figure 4.35.
Figure 4.34 pCMV-β-gal plasmid used to normalise transfections

Diagram of the β-gal plasmid with a β-lactamase gene and a β-galactosidase gene driven
by a CMV promoter.
Figure 4.35 Effects of E2 and ER on TGM2 activation
Normalised Luciferase Activity
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HeLa cells were transfected with 2880ng plasmid (ERE-TATA, pGL4.26 or TGM2luc), 0 or 20ng ERα, along with 100ng CMV-βgal. Total DNA was 3μg/triplicate. After
24hrs cells were treated with vehicle (V) or 10nM Estradiol (E2) with 1µM 4OHT or
1µM ICI and then harvested and assayed for luciferase and β-gal activity. The effect of
ERα on the activation of TGM2 was evaluated. Results are expressed as normalized
luciferase activity (normalized with β-galactosidase for transfection efficiency) +/standard deviation per triplicate sample of cells. Note: pGL4.26 transfection was not
carried out for the E2/4OHT or E2/ICI treated cells.
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From the graph we can see there is no significant activation of the TGM2
plasmid (p=0.32). However there is significant activation of the positive control ERETATA-luc by E2 (p<0.01) and repression of ERE-TATA-luc by 4OHT (p<0.01). This
experiment was repeated a further 3 times in HeLa cells without any significant
activation of pTGM2-luc.
This experiment was repeated in both HeLa cells and Skbr-3 cells using the
ligand ATRA (All-Trans Retinoic Acid), a known activator of TGM2 [89]. The results
of this experiment are presented in Figure 4.36, which shows significant activation of
the control plasmid ERE-TATA-luc by E2. However ATRA did not produce any
significant activation of the TGM2 plasmid. One possible explanation for this is that as
the location of the retinoid response element on TGM2 has not been fully established it
may be further upstream than the sequence included in this plasmid.
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Figure 4.36 Treatment of transfected cells with ATRA
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Skbr-3 cells were transfected with 2880ng plasmid (ERE-TATA, pGL4.26 or TGM2luc), 0 or 10ng ERα, along with 100ng CMV-βgal. Total DNA was 3μg/triplicate. After
24hrs cells were treated with vehicle (V) or Oestradiol (E2) or ATRA and then
harvested and assayed for luciferase and β-gal activity. The effect of ERα on the
activation of TGM2 was evaluated. Results are expressed as normalized luciferase
activity (normalized with β-galactosidase for transfection efficiency) +/- standard
deviation per triplicate sample of cells and expressed as mean fold change over vehicletreated cells.
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Oestrogen Receptor positive cells (MCF-7) were used in the following
transfection experiment. ER positive cells were used here as previous experiments failed
to show TGM2-luc activity. To out rule poor ER transfection efficiency as a cause of
this, cells containing the ER are used. MCF-7 cells were transfected with the TGM2luc, ERE-TATA-luc and pGL4.26 plasmids. Following transfection cells were treated
with the ER ligands, E2, TAM, and ICI (Figure 4.37). The aim of this experiment is to
analyse the effects of ER ligands and the oestrogen receptor on the transcriptional
activity of cloned TGM2-luc plasmid.
Figure 4.37 Transfection of TGM2-luc in MCF-7 cells
Normalised Luciferase Activity
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MCF-7 cells were transfected with 2900ng plasmid (ERE-TATA, pGL4.26 or TGM2luc) and 100ng CMV-βgal. Total DNA was 3μg/triplicate. After 24hrs cells were treated
with vehicle (V), 10nM Oestradiol (E2), or 1uM All-Trans Retinoic Acid (ATRA) with
1uM 4OHT or 1uM ICI, and then harvested and assayed for luciferase and β-gal
activity. The effect of E2 or ATRA on the activation of TGM2 was evaluated. Results
are expressed as normalized luciferase activity (normalized with β-galactosidase for
transfection efficiency) +/- standard deviation per triplicate sample of cells.
Although there is good activation of the ERE-TATA-luc with E2, there is no
significant activation of the TGM2-luc plasmid (p>0.05). Also ERE-TATA-luc
induction is inhibited by 4OHT, as shown here by a decrease in luciferase activity
(p<0.01). This experiment was repeated giving the same results as shown here. The
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putative ERE within the pTGM2-luc plasmid being tested may not be functional. This
may explain the lack of luciferase activity in pTGM2-luc transfected cells.

5 Discussion
Tamoxifen (TAM) has been used clinically for more than 30 years to treat breast
cancer, and for more than 10 years to reduce the risk of breast cancer in women at high
risk of developing this disease. The activities of TAM and its metabolites 4Hydroxytamoxifen (4OHT) and Endoxifen, in breast cancer have primarily been
attributed to their ability to inhibit ER signaling. Although clearly an ER antagonist in
the breast, TAM has agonist activity in other ER target tissues and as such preserves
bone mineral density but increases the risk for endometriosis and endometrial cancer,
blood clots, and stroke. However, it is not entirely clear how TAM, RAL, and other
SERMs exhibit tissue-specific or promoter-specific activities through a single signaling
pathway. This study aims to investigate the differential promoter-specific pharmacology
of TAM in the context of breast cancer cells using the TGM2 gene as a model.
The results of this study reveal the differential control of the TGM2 gene by the
oestrogen receptor and TAM in the context of breast cancer cells. Figure 4.7 shows that
ER/E2 induces expression of RET and TGM2 but co-treatment with TAM will inhibit
RET but not TGM2. These results are interesting as we would expect all ER-regulated
genes to be inhibited by TAM in breast cancer cells. Therefore TGM2 may be the first
in a class of ER-regulated gene differentially regulated by TAM.
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A further investigation into these findings leads us to examine the requirement
of ER in the activation and inhibition of TGM2. An ER plasmid was transfected into ER
negative cells breast cancer cells (MDA-231), using a β-gal plasmid as a control. ERtransfected cells showed a significantly higher induction of TGM2 when treated with E2
(p<0.01) over cells transfected with the β-gal plasmid (Figure 4.8). However although
there was good activation of the WISP2 ER-regulated gene (control), there was only a
slight but significant increase in TGM2 induction. One possible cause of this may be
poor transfection efficiency, where an insufficient amount of ER required for TGM2
activation was present in the cell.
To explain the failure of TAM to inhibit ER-induced activation of TGM2 we
investigated the hypothesis that activated AhR is preventing inhibition of this gene by a
process of ER-AhR cross-talk. Figure 4.9 confirms that TAM is a potent activator of
AhR, as shown by the large fold increase in CYP1A1 (AhR-responsive gene) induction.
Figure 4.10 shows the effects of the AhR agonists, TAM and BNF on TGM2 mRNA
expression. These results clearly show that activated AhR alone is not sufficient to
maintain expression of TGM2. Although AhR is activated by TAM, it does not lead to
transcription of TGM2 therefore we can out rule the involvement of AhR in TGM2 gene
induction.
Analysis of other related SERMs revealed that Endoxifen and 4OHT also show
similar patterns to Tamoxifen in inhibiting ER mRNA induction of TGM2 while the
SERM Raloxifene was very effective in inhibiting this induction. The fact that Endox
and 4OHT both have similar patterns to TAM is not surprising given that they are
structurally related to TAM.
Although RAL functions in the same way as TAM, they have different patterns
of activation and inhibition in different cells. RAL acts as an agonist in bone and an
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antagonist in the uterus while TAM acts as an agonist in the bone and uterus (Table
1.1). Our findings show that RAL and TAM have different inhibition patterns of the
TGM2 gene in breast cancer cells. The prevailing question in this study is why two
similar but distinct SERMs cause different activation patterns with the same gene in the
same cells. While we know that upon E2 treatment, ER and other cofactors are recruited
to gene regulatory regions to modulate gene expression, but depending on the promoter
context and cellular background, TAM and E2 can regulate gene expression in a manner
similar to or different from RAL/E2. It has been shown using phage-display/ELISA
technology that the structures of the TAM-ER and RAL-ER complexes are not identical
and show important differences that may contribute to differences in their patterns of
gene regulation [26]. This would explain why RAL but not TAM can act as an
antagonist in the uterus. It does not fully explain however why TAM has different
patterns on the TGM2 gene in breast cancer cells while inhibiting all other ER-regulated
genes. SERMs act in a promoter and cell-context specific manner. We hypothesise that
TGM2 must have an oestrogen receptor responsive element in its regulatory region
which is slightly different to that in other ER-regulated genes. Therefore binding of
RAL/ER to TGM2 promoter would allow for the binding of co-repressors which inhibits
gene transcription whereas binding of TAM-ER to the gene does not recruit corepressors, instead allowing for the recruitment of a co-activator complex leading to
transcription.
We set out to investigate the effects of TAM and its related compounds on the
TGM2 gene expression in breast cancer cells. Our data highlights the differential
pharmacology of TAM in the regulation of TGM2. However now the prevailing
question is what makes TGM2 different from other ER-regulated genes. In order to
accomplish a better understanding of TAM/ER action in breast cancer, TGM2 may be
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used as a model gene which does not conform to the expected characteristics of an ERregulated gene. To investigate TGM2 further, we analysed the genomic sequence of its
regulatory region.
To understand the basis for the differential regulation of this gene we analysed
2kbs of the sequence upstream of the TGM2 promoter. Two possible ER regulatory
regions were located, one putative ERE (8 out of 10 match) and one AP-1 site (6 out of
7 match) (Figure 1.13). These binding sites are a slight deviation from the canonical
binding site. This slight difference in sequence may be a contributing factor to the
differential pharmacology seen in these results. If the ER is indeed binding to these
sequences we would not expect a typical binding site. ERα is known to activate AP-1
controlled genes when bound by either E2 or TAM in the cytoplasm [90]. However our
results show E2 is required for TGM2 up-regulation. This finding may out rule ER AP-1 as a mode of TGM2 activation.
Transfections were performed in MCF-7, HeLa and Skbr-3 cell types using the
cloned TGM2-luc plasmid. Each experiment was designed to investigate specific
requirements of TGM2 activation and inhibition. Our constructed plasmid did not show
any significant luciferase activity in any of the experiments. As we have confirmed that
the plasmid has the correct insert and orientation (Figure 4.31), these results may
indicate that the ER is not actually binding to the sequence within the cloned 1.7kb
TGM2 5‟ flanking region. However it is possible that the required coactivators or
transcription factors are not present in sufficient quantity to induce transcription or
perhaps other NRREs are required. As discussed earlier, two other proposed ER binding
sites are present in the vicinity to the TGM2 gene, which was previously identified using
chip-on-chip data shown in Figure 4.14 [35]. It is entirely possible that the ER is driving
transcription of this gene through one of these putative binding sites as the ER can act at
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a large distance from the promoter [91]. Further study is required to investigate the role
of these putative ER binding sites in TGM2 regulation.
Although other studies have examined TGM2 involvement in apoptosis, cell
development and tumour migration and development, this is the first study on the
hormonal regulation of TGM2 in the context of SERMs in breast cancer. Our findings
indicate important differences in the regulation of TGM2 by E2 and SERMs that might
impact on the activity of TGM2 in breast cancer cell migration and metastasis.
In conclusion our data show the differential pharmacology of TGM2 in relation
to TAM and Endoxifen. Cell culture experiments have demonstrated the role of ERα in
TGM2 activation. We have identified two putative ER binding sites with the 5‟ flanking
region, an ERE and an AP-1 site and cloned this region into a luciferase vector. Finally
our results suggest that the ER may not be binding to this region and instead my activate
transcription from a more distal binding site.
The continued mRNA expression of TGM2 in the presence of ER/TAM may
have clinical significance due to its role in tumour suppression and prevention of
metastasis, as discussed earlier. Further research is required to determine the role of
TGM2 in tumour cells.
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7 Appendix
Table 7.1 UV quantification of isolated RNA (Raw data)
Sample
ID
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15

Net Abs
260.0nm
0.1668
0.1396
0.1905
0.1285
0.1220
0.1248
0.1359
0.1434
0.1316
0.1547
0.1425
0.1328
0.1718
0.1620
0.1639

Net Abs
280.0nm
0.0744
0.0613
0.0847
0.0557
0.0553
0.0548
0.0594
0.0625
0.0579
0.0672
0.0627
0.0601
0.0753
0.0732
0.0728

260.0/280.0
2.2419
2.2773
2.2491
2.3070
2.2061
2.2774
2.2879
2.2944
2.2729
2.3021
2.2727
2.2097
2.2815
2.2131
2.2514

Dil
Factor
25.000
25.000
25.000
25.000
25.000
25.000
25.000
25.000
25.000
25.000
25.000
25.000
25.000
25.000
25.000

Conc.
µg/ml
166.8
139.6
190.5
128.5
122.0
124.8
135.9
143.4
131.6
154.7
142.5
132.8
171.8
162.0
163.9

RNA samples were diluted 1/25 in TE buffer prior to quantification. All RNA samples
in these studies have a 260:280nm ratio of between 2.0 – 2.5
Table 7.2 Volumes required for iScript RT-PCR reaction
sample
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15

treatment
control
10nM E2

100nM 40HT

100nM BNF

E2 + 4OHT
E2 + BNF

Time
1hr
2hr
4hr
6hr
1hr
2hr
4hr
6hr
1hr
2hr
4hr
6hr
6hr
6hr

µg/ml RNA
166
139
190
128
112
124
135
143
131
154
142
132
171
162
163
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µl/1µg
RNA
6
7.2
5.3
7.8
8.9
8.1
7.4
7
7.6
6.5
7
7.6
5.8
6.2
6.1

µl H20
9
7.8
9.7
7.2
6.1
6.9
7.6
8
7.4
8.5
8
7.4
9.2
8.8
8.9

